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Abstract 
 
 
Alzheimer's Disease (AD) is a neurodegenerative disorder that is associated with 
elderly, being designated as multifactorial disease. The current therapy that is used to treat 
AD is based mainly on the administration of acetylcholinesterase (AChE) inhibitors. 
However, it is noted that this is not so effective. Thus, a promising therapy for treating this 
neurodegenerative disease may consist in administration of drugs that act on more than a 
target on biochemical scenery of AD. Therefore, in this work, the design, synthesis and 
evaluation of xanthones and flavones as antioxidants with concomitant AChE inhibitory 
activity were accomplished. 
 Firstly, in this work, the hydroxylated xanthone (ICX1) was synthesized as well as 
its methylated derivative ICX2. Subsequently, amino derivatives of ICX2 and baicalein (B) 
were also obtained by Mannich reaction. The structures of the synthesized compounds 
(ICX1; ICX2; ICX2a and ICB1) were established by IR and NMR. 
 Antioxidant activity of the obtained compounds and of a small library of other 
structure related aminoxanthone derivatives (PPX1; PPX2; PPX3; PPX4; PEX1 and PEX3) 
previously synthesized in our research group was assessed by different methods. 
Xanthones ICX1 and ICX2a showed antioxidant activity by chelation iron and copper ions, 
while xanthones PEX1 and PEX3 only had moderate antioxidant activity by scavenging free 
radicals. As the precursor baicalein (B), the amino derivative ICB1 exhibited antioxidant 
effect through scavenging free radicals and by chelation metal ions.  
 AChE inhibitory activity of xanthone and flavone derivatives was also evaluated. 
Among all tested compounds, Mannich base derivatives ICX2a and ICB1 showed moderate 
effect against AChE, being ICB1 the most active compound. From this study, ICX2a and 
ICB1 emerged as potential dual agents.  
In the current work, docking studies of ICB1 with AChE were performed in order to 
study its binding mechanism.  
In conclusion, aminated xanthones and flavones provide an adequate scaffold for 
the design of dual agents with antioxidant and AChE inhibitory activities. Therefore, the 
compounds obtained in this work may be served as model for the design of new xanthonic 
and flavonic derivatives with potential dual activity for treating AD.  
 
Keywords: Alzheimer; Xanthones; Flavones; Antioxidant; Acetylcholinesterase. 
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Resumo 
 
A doença de Alzheimer é uma doença neurodegenerativa associada com o avanço 
da idade, sendo designada como uma doença multifatorial. A terapêutica que atualmente 
é utilizada para tratar esta doença baseia-se principalmente na administração de inibidores 
da enzima acetilcolinesterase. No entanto, constata-se que esta não é totalmente eficaz. 
Assim, a administração de fármacos que atuem em mais do que um alvo no cenário 
bioquímico da doença de Alzheimer poderá ser considerada uma alternativa terapêutica 
promissora. Pelo exposto, nesta tese foram efetuados o planeamento, síntese e avaliação 
de xantonas e flavonas como antioxidantes com concomitante atividade inibidora da 
acetilcolinesterase.  
Neste estudo foi sintetizada a xantona hidroxilada (ICX1), bem como o seu derivado 
metilado ICX2. Derivados aminados de ICX2 e da baicaleína (B) foram também obtidos 
através da reação de Mannich. A estrutura dos compostos sintetizados foi estabelecida 
através da aplicação conjunta de diversas técnicas espetroscópicas, nomeadamente IV e 
RMN. 
A atividade antioxidante dos compostos obtidos e de uma pequena biblioteca de 
outros derivados aminoxantónicos sintetizados anteriormente no nosso grupo de 
investigação (PPX1; PPX2; PPX3; PPX4; PEX1 and PEX3), foi avaliada por diferentes 
métodos. As xantonas ICX1 e ICX2a apresentaram atividade antioxidante como agentes 
quelantes de iões metálicos, enquanto PEX1 e PEX3 tiveram atividade antioxidante 
moderada através da captação de radicais livres. Tal como a baicaleína (B), o seu derivado 
ICB1 exibiu um efeito antioxidante através da captação de radicais livres e por quelação 
de iões metálicos.  
A atividade inibidora da acetilcolinesterase dos derivados xantónicos e flavónicos 
foi também avaliada. De entre os compostos testados, as bases de Mannich ICX2a e ICB1 
apresentaram um efeito moderado, sendo o composto ICB1 o mais ativo. Deste estudo, os 
compostos ICX2a e ICB1 surgiram como potenciais agentes dual. 
No presente trabalho, foram também realizados estudos de docking do composto 
mais ativo (ICB1) com a acetilcolinesterase com o objetivo de estudar o seu mecanismo 
de ligação. 
Em conclusão, as xantonas e flavonas aminadas mostraram possuir um esqueleto 
apropriado para o design de agentes dual com atividades antioxidante e inibidora da 
acetilcolinesterase. Os compostos obtidos neste estudo podem servir como modelos para 
o planeamento de novos derivados xantónicos e flavónicos com potencial atividade dual 
para o tratamento da doença de Alzheimer.  
Palavras-chave: Alzheimer; Xantonas; Flavonas; Antioxidante; Acetilcolinesterase.  
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Outline of the Dissertation 
 
 
The present dissertation is organized in seven main parts: 
 
Chapter I. General Introduction 
 
In this chapter, a brief introduction of some key concepts about Alzheimer's disease, 
as well as the therapy that is currently used in this disease are presented in section 1.  
A brief description of the chemistry of xanthones and flavones as well as their 
importance in Medicinal Chemistry is highlighted in sections 2 and 3.  
In section 4, xanthones and flavones with anticholinesterase and antioxidant 
activities and/or both dual effects are reviewed. 
 
Chapter II. Aims and Overview 
 
 This chapter summarizes the main objectives of this work. 
 
Chapter III. Synthesis 
 
The chapter is divided into two parts: one part concerning the xanthonic derivatives 
(section 1) and another part related to flavonic derivatives (section 2). In the section 1.1., a 
brief introduction about general methodologies that are available for the synthesis of 
xanthones is presented. In section 1.2., the results obtained for the synthesis of xanthone 
derivatives and their structure elucidation are described and discussed.  
The section 2, starts with a short introduction about general methodologies for the 
synthesis of flavones. In section 2.2., the results obtained for the synthesis of the amino 
derivative of baicalein and its structure elucidation are present and discussed.  
In section 3, the general methods, reagents and procedures used for the synthesis 
are described. 
In section 4, some conclusions about the results obtained in the synthesis of 
xanthone and flavone derivatives are draw.  
 
 
 
xix 
 
Chapter IV. Biological Activity 
 
Chapter four is divided into two parts: one part concerning the antioxidant activity 
and another part related to the AChE inhibitory activity of xanthones and flavones. 
The section related to the antioxidant activity starts with an outline of the methods 
that are available for evaluation of the antioxidant activity (section 1.1.). In section 1.2., the 
results obtained for antioxidant activity of xanthone and flavone derivatives are shown and 
discussed. 
The section 2 is related to AChE inhibitory activity and starts with a brief introduction 
where the available methods to evaluate this activity are summarized. The results obtained 
in assays with xanthone and flavone derivatives are presented and discussed in section 
2.2.. 
In section 3, are indicated and discussed the results concerning the compounds that 
showed dual activity.  
In section 4, the procedures used for the biological activity evaluation are described. 
This chapter ends with the main achievements of the present work.  
 
Chapter V. Docking Studies 
 
This chapter starts with a description and a discussion of the results obtained in the 
docking studies of the most active compound with AChE. 
 In section 2, the general methods applied for the molecular docking studies are 
indicated.  
In section 3, some conclusions about the results obtained in these docking studies 
are draw.    
 
Chapter VI. Final Conclusions and Future Work 
 
This chapter consists of a general conclusion of the dissertation. 
 
Chapter VII. References 
 
The references are presented at the end of this thesis. The references followed the 
ACS American Chemical Society style guide.  
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1. Alzheimer´s disease (AD) 
 
 
In 1906, Alois Alzheimer, a German psychiatrist, was the first to describe this 
pathology 1. AD is a neurodegenerative disease which is associated with age and it is the 
cause of most cases of dementia observed in elderly 2,3. Two types of AD were described, 
differing by the number of individuals in a family who are affected by this pathology. One is 
called “familiar” (if several family members have AD) and the second one is referred as 
“sporadic” (when only one member of the family or a few people suffer from AD) 4. Typically, 
people with this disease have a progressive synaptic dysfunction, which may lead to the 
death of neurons in the neocortex, limbic system and subcortical regions of the brain. These 
disturbances in the brain, therefore, are the cause of some symptoms, such as personality 
and cognitive changes and memory deficits 2. As this pathology is caused by a number of 
factors, including genetic, environmental and endogenous usually it is designated as a 
multifactorial 4. 
More recently, a lot of research in the area of neurodegenerative diseases, 
particularly in AD, has been made in order to understand its pathogenesis 4,5.For most 
scientists and pathologists the main characteristics associated with this disease are the 
formation of senile plaques (SP) and neurofibrillary tangles (NFT) 4-6.  
SP are deposits composed of amyloid beta (A) peptide and the formation of these 
protein aggregates is currently explained by the “amyloid cascade hypothesis”. Figure 1 
illustrates the formation of A peptide according with this hypothesis, as well as its 
neurotoxicity 4,6. 
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Figure 1. A peptid and SP formation according with “amyloid cascade hypothesis”. A peptide 
results from successive proteolytic cleavages by  -secretase and -secretase of amyloid precursor 
protein (APP). The neurotoxicity of A deposites in the SP is related to the fact that it promotes the 
activation of microglial cells; they can accumulate in mitochondrion promoting dysfunction leading 
ultimately to the neuronal death (adapted 4). 
 
 
NFT in AD are composed of straight filaments and paired helical filaments (PHF), 
which are composed of an abnormal hyperphosphorylated isoform of the microtubule - 
associated protein  (MAP) 4,6,7. The formation of NFT in AD is summarized in Figure 2.  
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Figure 2.  NFT formation.  protein has the function of stabilizing the neuronal microtubules, allowing 
them to play their role in cellular processes, namely the establishment of cell polarity and intracellular 
transport. The phosphorylation of  protein by protein kinases in the microtubule binding domain 
leads to the dissociation of this protein from microtubules and the formation of aggregates, which will 
culminate in the formation of NFTs. These molecular events will result in decrease of microtubules 
functions; disruption of neuronal transport; synaptic loss and, ultimately in cell death (adapted 8).  
 
 
In addition to the SP and NFP, AD is currently characterized by other hypotheses 
that attempt to explain the pathogenic nature of this disease. It is considered that 
inflammation, oxidative stress, metal ion dyshomeostasis and loss of cholinergic neural 
transmission contribute, in an interconnected way, to the development and the symptoms 
that characterize this disease 4,9. 
Regarding neuroinflammation, it has been considered as a hallmark of AD. In this 
kind of neuroinflammation, microglial cells are those which have attracted great interest 
from researchers 4. These cells are defined as cells of the immune system of the Central 
Nervous System (CNS) because they constitute the population of resident macrophages in 
the CNS. Particularly, in AD, microglial cells play a dual role. On one hand, these cells have 
a neuroprotective role by degradation of A by phagocytosis. On the other hand, A can 
lead to activation of these cells, which produce several toxic substances, such as cytokines, 
chemokines and neurotoxins 10. This proinflammatory activity attenuates the phagocytic 
activity of microglial cells, which contributes to neuronal degradation observed in AD. Due 
to the neuroprotective role of the microglial cells, the scientists considered that therapies 
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involving inhibition of the recruitment of monocytes and macrophages may not be adequate 
4,10. 
Another pathogenic feature of AD is the oxidative stress. Patients with this condition 
have oxidative damage in all biomolecules (nucleic acids, lipids, carbohydrates and 
proteins) 11. This oxidative damage will lead to a secondary excessive oxidative stress 
resulting from mitochondrial dysfunction, lack of energy supply, disruption in antioxidant 
defenses, and free radicals induced by A peptide or inflammation. The metal ions also 
contribute to oxidative stress, since they induce the production of reactive oxygen species 
(ROS) via the Fenton reaction. Specifically, copper ion with other metallic ions, in addition 
to promoting oxidative damage still have the ability to interfere with protein aggregation 
processes (A peptide and APP) in AD 4,11,12. 
Moreover, it has been found that the increase of acetylcholine (Ach) release at 
cholinergic synapses has favored behavioral and cognitive improvement in Alzheimer 
patients. These results have been achieved through the use of acetylcholinesterase 
inhibitors (AChEI). This enzyme, which is released into the synaptic cleft by activation of 
presynaptic and postsynaptic cholinergic receptors, has the function to cleave the 
neurotransmitter ACh into choline and acetic acid. Inestrosa et al. (1996) described another 
function of acetylcholinesterase (AChE), which is designated as "non-classical function” 13. 
According to these researchers, this enzyme will act as a "pathological chaperone", 
because it will be responsible for stimulating the aggregation of A peptide by direct 
interaction of its peripheral anionic site (PAS) with the peptide fibrils 4,9,13.  
Finally, other enzyme that is also involved in the pathogenesis of AD is the 
monoamine oxidase (MAO) 14,15. This enzyme is responsible for catalyzing the deamination 
of neurotransmitters (noradrenalin, dopamine and serotonin), and in the humans, MAO 
exists as two isozymes: MAO-A and MAO-B 14,15. These two isozymes have different amino 
acidic constituition; different distribuition and different substrate specificity, but both of them 
can be found in and outside the CNS 14,15. In patients with AD, there was a high MAO activity, 
being that this enzyme acted as a hallmark of behavioral characteristics. It has been found 
that MAO is also responsible by causing cognitive dysfunction and disorders of the 
cholinergic neurons and it is associated with the formation of A peptide and NFTs in this 
disease14. Figure 3 summarizes the main hallmarks of AD. 
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1.1. Alzheimer’s disease therapy 
 
 
Considering the above hypotheses that contribute to the arising and development of 
AD there are several targets that may be associated with the current therapy. The most 
common drugs used in therapy are AChEI, inhibitors of -secretase and -secretase, 
antioxidants, chelating agents and inhibitors of enzymes involved in the phosphorylation of 
 protein 4. 
Nowadays, a very common therapy for AD is based on the administration of AChEI. 
Tacrine, donepezil, rivastigmine and galantamine are AChEI used as drugs for the 
treatment of AD approved by the Food and Drug Administration (FDA) (Figure 4) 4,16. 
However, only rivastigmine has been approved by the European Agency for the Evaluation 
of Medical Products (EMEA)1. Although tacrine has been the first AChEI to be approved by 
the FDA, is currently rarely used due to its hepatotoxicity 4,16. It should be noted that 
donepezil, rivastigmine and galantamine belong to the same therapeutic class, but have 
different pharmacodynamic and pharmacokinetic profiles. In this way, donepezil is a non-
competitive reversible inhibitor of AChE; galantamine is a selective reversible inhibitor of 
                                                          
1http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001183/human_med_001
212.jsp&mid=WC0b01ac058001d124 
Figure 3. Hallmarks of AD.  
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AChE and a positive allosteric modulator of nicotinic receptors of pyramidal neurons and 
rivastigmine behaves as a slowly inhibitor of both AChE and butyrylcholinesterase (BuChE) 
16. Another alternative therapy to AChEI is the administration of memantine (Figure 4), a 
non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptor. This also represents 
an effective therapy for the treatment of AD because in this pathology, an excessive 
glutamate release is associated with an intense activation of the NMDA receptor with 
consequent long - lasting influx of Ca2+ into neurons. In turn, this intracellular accumulation 
of Ca2+ leads to the activation of a cascade of events that contribute to increased cell death 
4,16. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Due to the multifactorial nature of AD, an effective therapy does not involve a single 
agent acting on a single target. Concerning this concept, three types of therapies that 
enhance the efficiency of treatments have been reported: “multiple-medication therapy” 
(MMT), “multiple-compound medication” (MCM) and “multi-target-directed ligands” 
(MTDLs) 4,17. The first approach (MMT) consists in a therapy, where two or three drugs 
acting on different molecular targets are administered separately in different pharmaceutical 
formulations 4,17. The MCM approach refers to the administration of a single pharmaceutical 
formulation which comprises several active substances with different molecular targets 4,17. 
The last approach (MTDLs) involves the administration of a single chemical entity which 
Figure 4. Chemical structure of drugs used in current therapy of AD. 
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can simultaneously modulate multiple molecular targets 4,17,18. MCM therapy can be 
considered as more advantageous than MMT therapy, since it allows a simple dosage 
application. MTDLs approach has demonstrated to be more suitable for treating complex 
diseases, such as neurodegenerative diseases, because the referred compounds show the 
ability to interact with multiple molecular targets responsible for the pathogenesis of the 
disease 4,17,18. 
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2. Xanthone derivatives 
 
 
2.1. Chemistry of xanthones 
 
 
In 1855, Schmidt, a German scientist, has isolated a crystalline compound from the 
pericarp rind of the mangosteen fruit. Due to its yellow color, the scientist has designated 
the compound by xanthone, which derives from the Greek word "xanthos" (yellow). 
Xanthones are secondary metabolites that may be found in certain families of higher plants, 
lichens and fungi 19,20.  
Chemically, xanthones are a class of oxygenated heterocyclic compounds with a 
dibenzo--pyrone scaffold (Figure 5) 21,22. 
 
 
 
 
 
 
 
 
 
 
 
 
This class of secondary metabolites can be derived from different biosynthetic 
pathways. The biosynthetic pathways of xanthones have been widely discussed by different 
authors for forty years and have been reported in several reviews 23-28. In general, it is 
proposed that xanthones from higher plants derived from a mixed acetate-shikimate 
pathway and xanthones from fungi and lichens are acetate-derived 22-24. 
 The natural xanthones can be classified into six groups according to their 
substitution pattern: simple oxygenated xanthones, xanthone glycosides, prenylated 
xanthones, xanthonolignoids, bisxanthones and miscellaneous xanthones 20,21. 
 In addition to natural xanthones, there are a large variety of xanthones of synthetic 
origin. Xanthones obtained by synthesis may hold from simple substituents (hydroxy, 
methoxy, methyl, carboxy) to more complex substitution patterns (epoxide, azole, 
methylidenebutyrolactone, aminoalcohol, sulfamoyl, methylthiocarboxylic acid and 
dihydropyridine) 21. 
Figure 5. The structure of xanthone with numbering. 
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3. Flavone derivatives 
 
 
3.1. Chemistry of flavones 
 
 
In 1895, von Kostanecki and Tambor were the first to coin the term “flavones” 29 for 
natural products isolated from different kind of fruits and vegetables 30. 
Chemically, flavones are a class of flavonoids based on the backbone of 2- 
phenylchromen-4-one (2-phenyl-1-benzopyran-4-one), which have a three-rings referred as 
A, B and C (Figure 6) 30,31.  
 
 
 
 
 
 
 
 
 
 
 
 
Flavones and all other flavonoids derived mainly from a biosynthetic pathway, where 
the crucial reaction is the condensation of three molecules of malonyl-CoA with one 
molecule of p-coumaroyl-CoA to give a chalcone intermediate (Figure 7). From this 
intermediate is formed flavanone. Derived from the flavanone structure, all other classes of 
flavonoids, including flavones, can be generated (Figure 7) 29,30.  
 
Figure 6. Flavone scaffold. 
 CHAPTER I. General Introduction 
11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Biosynthetic pathway of flavones. Enzymes that are involved in this pathway are 
abbreviated as follows: CHS, chalcone synthase; CHKR, chalcone polyketide reductase; CHI, 
chalcone isomerase; FHT, flavanone 3-β-hydroxylase; FNS, flavone synthase; FLS, flavonol 
synthase; LAR, leucoanthocyanidin reductase; ANR, anthocyanidin reductase; IFS, isoflavone 
synthase; IFD, isoflavone dehydratase (adapted 29). 
 
 
Natural flavones have different substitution patterns and they are classified into 
several subgroups according to hydroxylation, O-methylation, C-methylation, 
isoprenylation, methylenedioxy or O- and C-glycosides substitution 29. This structural 
diversity of flavones is responsible for the wide variety of biological activities that this class 
of flavonoids presents 32. Due to this, several research groups have taken flavone as lead 
compound for the synthesis of new derivatives with different functional groups at different 
positions on the flavone moiety 30. For various natural and synthetic flavones, a variety of 
pharmacological activities have been evaluated and demonstrated, such as anti-
inflammatory, anti-oestrogenic, anti-allergic, antioxidant, vascular, antitumor, cytotoxic, 
antimicrobial, antidiabetic, antiasthmatic and anti-ulcer activities 30,31. Flavone moiety can 
be designated ‘skeleton key’ because it is an important core in many compounds that act 
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at different targets. In this context, flavones can be also considered a privileged structure in 
drug development, because flavone derivatives, depending of their substitution patterns, 
can reveal various biological / pharmacological activities, since they can act on several 
molecular targets that are involved in the pathology of different diseases 30,33.  
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4. Xanthone and flavone derivatives related with Alzheimer´s disease 
 
 
Xanthones and flavones can be considered as privileged structures since their 
derivatives are capable of interacting with several different targets 20,30,31,34. 
Xanthonic and flavonic derivatives (natural and synthetic) that act on molecular 
targets of neurodegenerative diseases have been widely studied and explored 34-39. 
Recently, researchers have given special attention to these derivatives as potential agents 
for the treatment of AD 38. Some xanthones and flavones have been shown to inhibit AChE 
and MAO enzymes 37,38,40-44; to chelate metal ions 45,46; to scavenge ROS 38,47-49 and to inhibit 
the aggregation of A peptides 50-53. 
Despite all these activities, the association between AChE inhibition and antioxidant 
activity has been considered as an attractive strategy for the development of new agents 
that can combat AD 38,39,44. Accordingly, more relevance will be given to xanthonic and 
flavonic derivatives with anticholinesterase and antioxidant activities, as well as those with 
dual activity. 
 
 
4.1. Xanthone and flavone derivatives with anticholinesterase activity 
 
 
According to the cholinergic hypothesis, patients with AD have a loss of cholinergic 
synaptic transmission which is also associated with low levels of ACh in the brain. This 
hypothesis is explained in Figure 8, as well as the action of AChEIs that are used in current 
therapy of AD 9. However, these drugs have several disadvantages (Figure 8) and 
consequently, scientists have searched for more potent and selective compounds which 
are capable of inhibiting AChE.  
Particularly, in recent years, xanthonic derivatives that inhibit AChE have been 
explored 54,55.   
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Figure 8. Mechanism of action of ACh and molecular target of the current therapy of AD. ACh that 
is released in the synaptic cleft will activate muscarinic (M1, M2 and M3) and nicotinic (N) receptors 
in presynaptic and postsynaptic neurons which results in increasing cognition. AChE whose function 
is to remove the ACh released into the synaptic cleft is the molecular target for AChEIs used in the 
current therapy of AD. However, AChEIs have various disadvantages, such as these drugs are able 
only to treat the early stages of mild or moderate degrees of AD; have several side effects and when 
cholinergic neurons are destroyed they tend to lose their therapeutic effect (adapted 4). 
 
 
Degen et al. (1999) developed their research in the area of AD, searching for new 
compounds based on arisugacin and on the conventional inhibitor tacrine (Figure 9). These 
scientists reported the synthesis of some dihydroxanthones, using the structures of 
arisugacin and tacrine as models (Figure 9) and respective evaluation of their inhibitory 
activity against AChE 54. These results are listed in Table 1.  
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Figure 9. Structures of arisugacin and tacrine. 
 
 
Considering compounds 1- 4 that differ only in one aromatic ring, it can be seen that 
xanthone 1 has the most steric bulkiness, whereas compounds 3 and 4 have bridged 
bicyclic structures in one of the aromatic rings. The compound 1 has a double bond and a 
bulky group compared to compound 2. However, compound 2 showed a lower IC50, being 
the more potent AChE inhibitor 54. 
Regarding compounds 5-10, that differ on the substituent on C-7, it was also verified 
that the derivatives 5 and 6 that have strong electron withdrawing groups (F, Cl) in one ring 
are those having a higher inhibitory activity against AChE 54. 
 
 
Table 1. Inhibitory activities of dihydroxanthones against AChE (adapted 54). 
Dihydroxanthonic  
Derivatives 
IC50 (M) 
 
Dihydroxanthonic 
Derivatives 
IC50 (M) 
 
 
 2.0 
 
 
0.32 
 
 
 
 2.0 
 
 
0.58 
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Dihydroxanthonic  
Derivatives 
IC50 (M) 
 
Dihydroxanthonic 
Derivatives 
IC50 (M) 
 
 
0.28 
 
 
 
0.24 
 
 
 
1.42 
 
 
1.12 
 
 
0.79 
 
 
0.82 
 
 
In 2004, Brühlmann et al. related the search of potent non-alkaloid inhibitors of 
AChE. In this study, a wide variety of natural products, including xanthones, was used. 
Among the active xanthones, xanthone 17 proved to be the most active compound (Table 
2). From these results, Brühlmann et al. (2004) concluded that the xanthonic scaffold would 
not be the single condition for this kind of activity. In addition, the inhibitory activity was also 
influenced by the substitution pattern (hydroxylation and methoxylation) in the tricyclic 
hydroxy-methoxy-xanthones (11, 12, 13, and 14). The presence of an additional pyran ring 
linked to the xanthonic nucleus possessing a hydrophobic side chain like in xanthone 17 
also appears to be a factor which improved the anticholinesterase activity 41. 
 
 
 
 
 
 
 
Table 1 (continuation) 
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Table 2. Natural xanthonic derivatives as potent AChE inhibitors (adapted 41). 
kic = values of inhibition constant for competitive inhibition; kinc=values of inhibition constant for 
non-competitive inhibition; Not determined (n.d.). 
 
 
In 2007, Piazzi et al. have discovered a new class of AChE inhibitors, using 
xanthostigmine (34) as lead compound. The anticholinesterase activity was evaluated for 
diverse non-carbamic xanthostigmine analogues (Table 3). The results obtained allowed to 
get some structure-activity assumptions. First, removal of the carbamic function from 
xanthostigmine allowed obtaining a reversible inhibitor (compound 18). Moreover, it was 
found that changing the size of the alkoxy side chain also influenced the anticholinesterase 
activity of these analogues (compounds 18-27). Finally, the substitution of the methyl group 
Xanthonic  
Derivatives 
Kic[M] Kinc [M] Xanthonic 
Derivatives 
Kic[M] Kinc [M] 
 
 
 
15.1  0.9 
 
 
44  10 
 
 
 
16.0  1.8 
 
 
53  12 
 
 
 
4.3  0.5 
 
 
15.4  0.1 
 
 
 
12.0  0.5 
 
 
28.7  1.5 
 
 
 
n.d. 
 
 
n.d. 
 
 
 
n.d. 
 
 
26.8  5.4 
 
 
 
n.d. 
 
 
1.9   1.4 
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on the amino function by an ethyl group did not change the ability of the compound 33 to 
inhibit the AChE 56. 
 
 
Table 3. Inhibitory activity of xanthostigmine analogues on isolated AChE (adapted 56). 
 
 
 
Compound n R R1 R2 R3 R4 R5 R6 IC50(M) 
18 3 H H Me H H H H 2.68 ± 0.09 
19 4 H H Me H H H H 6.25 ± 0.85 
20 5 H H Me H H H H 7.78 ± 0.54 
21 6 H H Me H H H H 2.89 ± 0.23 
22 7 H H Me H H H H 2.82 ± 0.61 
23 8 H H Me H H H H 10.3 ± 6.50 
24 9 H H Me H H H H 152 
25 10 H H Me H H H H 388 
26 11 H H Me H H H H 626 
27 12 H H Me H H H H 908 
28 7 OMe H Me H H H H 7.84 ± 0.51 
29 7 OMe OMe Me H H H H 2.32 ± 0.13 
30 3 H H Me OMe H H H 3.40 ± 0.51 
31 7 H H Me OMe H H H 2.18 ± 0.16 
32 7 H H Me H OMe H H 40.0 ± 3.80 
33 7 H H Et OMe H H H 3.15 ± 0.20 
34 3 H H Me H H H OCONHMe 0.00030 ± 
0.0001  
 
 
Based on eighty xanthostigmine analogues that had already been reported as 
inhibitors of AChE 56-59, Gupta and Mohan (2011) developed a 3D-pharmacophore model 
based in the virtual screening for the identification of selective inhibitors of AChE. In this 
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study, the pharmacophoric model Hypo 1 was identified as the best quantitative 
pharmacophore model (Figure 10). 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. 3D-Pharmacophoric model of AChE inhibitors. (A) The best quantitative pharmacophoric 
model, Hypo1. (B) Hypo1 with compound 35 (IC50 = 0.3 nM) 60. 
 
 
After validation of the model, a sequential virtual screening procedure was 
performed based on Hypo 1 pharmacophore in order to find AChE inhibitors that were able 
to bind to its active site (AS) and PAS 60. From this molecular docking studies, the 
xanthostigmine analogue 35 emerged has the most active inhibitor. Figure 11 shows the 
results obtained for the molecular docking studies with compound 35. As shown in Figure 
11, these studies reveal an hydrogen interaction between the quaternary nitrogen atom and 
Tyr334 of AChE; a water-mediated interaction between the NH of the amide group of 
compound 35 and Gln74 and a - interaction between the aromatic moiety of the xanthone 
and Trp279 of the PAS of AChE. Thus, the xanthone derivative 35 is a potent inhibitor of 
AChE and can also interact with the PAS and AS of AChE. These results therefore 
suggested that this compound was also able to interfere with the aggregation of A peptide 
60. 
 
 
 
 
 
 
 
 
(B) 
(A) 
  
(B) 
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Figure 11. Molecular docking studies with compound 35 and AChE 60. 
 
 
Urbain et al. (2008) isolated xanthones from Gentianella amarella ssp. acuta, and 
tested their inhibitory activity against AChE. All xanthones had a low inhibitory activity, 
except triptexanthoside C (36) (Figure 12), which inhibited AChE with IC50 = 13.8  1.6 M 
42.  
 
 
 
  Figure 12. Structure of triptexanthoside C. 
 
 
In 2009, Khan et al. evaluated the anticholinesterase activity of the macluraxanthone 
(37) (Figure 13). In this study, macluraxanthone was the compound that demonstrated a 
greater ability to inhibit AChE (IC50 = 8.47 M) in a non-competitive manner 61.  
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Molecular docking studies with this xanthone showed that the most energetically 
favorable binding mode of the macluraxanthone to the binding site of AChE has a free 
binding energy of -15.49 kcal/mol 61. In this study, the interactions between 
macluraxanthone and the several subsites of AChE (PAS, AS and acyl-binding pocket 
(ABP)) at 2D and 3D space were also analyzed (Figure 14) 61.  
As a result of this analysis, it was observed that two oxygen atoms of 
macluraxanthone (HO-5 and HO-6) were responsible for establishing bounds with important 
amino acid residues of the PAS (Tyr124 and Tyr72). Moreover, the existence of several 
hydrophobic interactions with aminoacidic residues of the subsites PAS, AS and ABP of 
AChE was also observed (Figure 14) 61. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Structure of macluraxanthone. 
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Figure 14. Docking analysis for macluraxanthone with AChE at 2D (A) and 3D (B) space. The 3D 
ribbon represents the enzyme, the yellow stick model is the most favorable binding mode of 
macluraxanthone, and the gray-sticks with numberings represent the interacting amino acid residues 
of the enzyme 61. 
 
 
More recently, Qin et al. (2013) synthesized various analogs of the 1,3-
dihydroxyxanthone by Mannich reaction of this building block with secondary amines and  
formaldehyde and evaluated the anticholinesterase activity of the derivatives. The results 
showed that 2-((diethylamino)methyl)-1-hydroxy-3-(3-methylbut-2-enyloxy)-9H-xanthen-9-
one (38) (Figure 15) was found to be one of the most active compound (IC50 = 2.60  0.13 
M) 34.  
 
 
 
 
 
 
 
 
 
Figure 15. Structure of compound 38. 
 
(B) (A) 
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This research group in order to determine the type of inhibiton of this xanthonic 
compound also made enzyme kinetics studies and molecular docking studies by using the 
3D crystal structures of human AChE (PDB code: 1EVE). Firstly, the analysis of enzyme 
kinetics demonstrated that compound 38 showed a mixed inhibition, in other words, it is 
able to bind to the AS and the PAS of AChE. Secondly, molecular docking studies showed 
the free binding energy corresponding to the most favorable binding mode of compound 38 
and the bindings that are established between compound 38 and the active site of AChE. 
These results demonstrated that the most favorable binding mode of compound 38 had a 
free binding energy of -7.14 kcal/mol and therefore, this binding mode was used for docking 
simulations (Figure 16A). As shown in Figure 16B, it can be seen that the compound 38 
extends into the deep cavity of the binding pocket of the enzyme, occupying the central 
hydrophobic region of the binding pocket of AChE composed of Tyr70, Tyr121, Trp279 and 
Phe290 residues. It was also observed that this xanthonic derivative extends for PAS which 
is situated near the Trp84 residue of the AS of the enzyme. Particularly, the aromatic ring 
of compound 38 establishes - interactions with Trp279 residue of the PAS of AChE 
(Figure 16C). Thus, these observations enabled to confirm that compound 38, in fact, 
showed a kind of mixed inhibition 34. 
 
 
 
 
 
 
 
 
 
Figure 16. Molecular docking studies for compound 38 with AChE. (A) Interactions of compound 38 
with active site of AChE. (B) The MOLCAD surface modeling with cavity depth potential of binding 
pocket of AChE. (C) The MOLCAD surface of the binding pocket with lipophilic potential 34. 
 
 
Diverse flavone derivatives have also revealed interesting AChE inhibitory activity 
62,63.  
 In 2011, Uriarte-Puevo and Calvo reviewed the AChE inhibitory activity of 128 
flavonoids (natural and synthetic):  41 flavones, 21 flavanones, 35 flavonols, 25 isoflavones 
and 6 chalcones (see Figure 7) 44. Among the reported flavonoids, flavones and isoflavones 
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were the compounds which showed higher activity against AChE. This suggests that the 
presence of a carbonyl group at C-4 appears to be important to AChE inhibitory activity. It 
can also be noted that flavones had greater AChE inhibitory activity than flavanones, 
indicating that the double bound at C2-C3 influences the inhibition of this enzyme 44. 
Considering all the studied flavones, 6,7-dimethoxy-2-[4-(piperidin-1-ylmethyl)-
phenyl]-4H-chromen-4-one (39) (IC50 = 0.034 µM) and 6,7-dimethoxy-2-[4-(pyrrolidin-1-
ylmethyl)-phenyl]-4H-chromen-4-one (40) (IC50 = 0.055 µM)  (synthetic compounds) were 
the most active compounds (Figure 17). These results reveal that the substituents like 
pyrrolidin-1-ylmethyl or piperidin-1-ylmethyl at C-4’ and the presence of methoxyl groups at 
C-6 or C-7 seem to favor the AChE inhibitory capacity of flavones 44,55.  
 
 
 
 
 
 
 
 
 
 
 
Concerning natural flavone glycosides, isolinariins A (41) and B (42)  isolated from 
Linaria reflexa, revealed to be potent  AChE inhibitors showing IC50 values of 0.27 µM and 
0.30 µM, respectively. These results suggested that rhamnoglycoside moiety may exert an 
essential role in the interaction of the compound with AChE (Figure 18) 44,64.  
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Structure of compounds 39 and 40. 
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More recently, Duan et al. (2014) synthesized new Mannich base derivatives of 
2’‑hydroxy-3,4,4’,6’-tetramethoxychalcone and 5‑hydroxy-7,3’,4’-trimethoxyflavone and 
evaluated their AChE inhibitory activities. The results showed that Mannich base analogues 
of flavone were more active than Mannich base derivatives of chalcone. Particularly, 
compounds 43 and 44 were the most active compounds with IC50 values of 0.54 and 1.39 
μM, respectively (Figure 19). These data highlighted the importance of the presence of 
N,N-diethyl or alicyclic amine (pyrrolindinyl ring) at C-6 of the flavone skeleton for enhance 
AChE inhibitory capacity 65. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Structure of compounds 43 and 44. 
Figure 18. Structure of compounds 41 and 42. 
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4.2. Xanthone and flavone derivatives with antioxidant activity 
 
 
AD is also associated with oxidative stress, which is responsible for causing various 
disturbances in the organism, such as inflammation, mitochondrial dysfunction and 
alterations of antioxidant defenses. Thus, in recent years, compounds with high antioxidant 
activity have been searched as possible drugs to be used in AD 4. Antioxidants are 
compounds that have the function of inhibiting at low concentrations the oxidation of 
molecules in a biological system 66. The antioxidants may, therefore, eliminate or prevent 
certain degenerative processes by several mechanisms, such as free radicals scavenging 
4,66. Among a variety of antioxidants, natural and synthetic xanthones and flavones 
derivatives have been widely studied in recent years. 
Xanthones have shown a high capacity to scavenge a variety of ROS and reactive 
nitrogen species (RNS); inhibit oxidant enzymes activity 36,49,67-69 and induce antioxidant 
enzymes activity 70,71. 
Over the years, many researchers have studied the antioxidant activity of xanthonic 
derivatives isolated from several plants. In the Review “Xanthones as Potential 
Antioxidants”, natural xanthones that have revealed antioxidant activity are recorded 36.  
According to this review, the majority of xanthones which possess antioxidant 
activity were isolated from different parts of Garcinia plants 36. Among the bioactive 
secondary metabolites isolated from Garcinia sp., prenylated xanthones, -mangostin (45) 
and -mangostin (46) (Figure 20) have been extensively reported for their diversity 
biological activities, including antioxidant activity 72-75. Jung et al. (2006) reported that -
mangostin was a more potent scavenger of peroxynitrite than -mangostin. These results, 
therefore, suggest that the presence of O-dihydroxyl system at C-6 and C-7 in -mangostin 
will be essential for this activity 36,76. 
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Figure 20. Structures of -mangostin (45) and -mangostin (46). 
 
 
It was also found that glycosylated xanthones showed antioxidant activity 36. In 2003, 
Pauletti et al., isolated three new C-glucopyranosylxanthones (Table 4) from Arrabidaea 
samydoides and evaluated their antioxidant capacity 77. The results of this study 
demonstrated that compounds 47 and 48 have the best antioxidant activity, whereas 
compound 49 has a lower antioxidant activity. It was also highlighted that compound 47 has 
a stronger ability to scavenge free radicals 77. Considering the structure-activity relationship 
of these xanthonic compounds, it can be concluded that the increase of the number of 
catechol or hydroxyl groups in the structure leads to a higher free radical scavenging activity 
77. 
 
 
Table 4. Antioxidant activity of new C-glucopyranosylxanthones isolated from Arrabidaea 
samydoides. 
 
 
 
Compound IC50(M) 
 
 
 
17.81 
 
 
 
 
 
25.45 
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Compound IC50(M) 
 
 
31.36 
 
 
 
Among all xanthonic derivatives isolated from Garcinia subelliptica, 1,4,5-
trihydroxyxanthone and symphoxanthone (Figure 21) were those that had a higher 
superoxide anion radical scavenging activity. This suggests that catechol group or 1,4-
dihydroquinone moiety are important for the scavenger activity of these xanthones 36,78,79. 
 
 
                                        
Figure 21. Structures of 1,4,5-trihydroxyxanthone (50) and symphoxanthone (51). 
 
 
In addition to the natural xanthones, several synthetic xanthones have demonstrated 
antioxidant activity. Some examples of synthetic xanthones with this biological activity, 
namely diarylxanthones and (poly)hydroxyxanthones, are presented in Table 5 36. 
 
 
 
 
 
 
 
 
Table 4 (continuation) 
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Table 5. Diarylxanthones and (poly)hydroxyxanthones analogues with antioxidant activity. 
Diarylxanthones (poly)Hydroxyxanthones 
  
52b R7= R8 = R10 = H; R9 = OH 53b R11=OH, R12=R13=R14=R15=H 
 
52c R7 = R8 = H; R9 = R10 = OH 53c R11=R12=R14=R15=H, R13=OH 
 
52d R7 = OH; R8 = R9 = R10 = H 53d R11=R12=OH, R13=R14=R15=H 
52e R7 = R9 = OH; R8 = R10 = H 53e R12=R14=R15=H, R11=R13=OH 
 
52f R7 = R8 = R10 = OH; R9 = H 53f R12=R3=R15=H, R11=R14=OH 
52g R7 = R8 = OH; R9 = R10 = H 53g R12=R13=R14=H, R11=R15=OH 
52h R7 = R8 = R9 = OH; R10 = H 
 
 
52i R7 = R8 = R9 = R10 = OH 
 
 
For all these xanthones, the antioxidant activity was dependent on the number and 
position of hydroxyl groups. Particularly, the antioxidant activity of diarylxanthones was 
influenced by the number and position of hydroxyl groups in D and E rings. Also, the 
presence of the catechol group in the D ring proved to be more important than the presence 
of this group in the E ring (compounds 52c and 52f showed a higher scavenger activity than 
compounds 52h and 52g) 49,80. 
Taking into account all these studies, in general, it can be concluded that xanthones 
possessing a higher number of hydroxyl groups on xanthonic skeleton, show increased 
antioxidant capacity. Moreover, another important structural characteristic that contributes 
to its antioxidant activity is the presence of catechol moiety on the xanthone nucleus 39. 
In addition to the xanthones, flavones also have the ability to act in oxidative stress 
through its antioxidant and protective activities 81. This biological activity of flavones has 
been extensively studied and, in recent years, several articles have reported flavones as 
strong antioxidants 30,38,81. Like other antioxidants (including xanthones), flavones can exert 
this activity by different mechanisms: prevention of initiation of oxidation by inhibiting 
superoxide anion formation, degrading hydrogen peroxide and chelating or reducing metal 
ions; or as chain breaking antioxidants through scavenging free radicals 82.  
Particularly, flavones scavenge free radicals (ROS and RNS) through two different 
ways: transfer of hydrogen atom from the flavone to the free radical or transfer of an electron 
from the flavone to the free radical 81. 
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Recently, Catarino et al. (2015) reviewed the major structural features of flavones 
that enhance their ability to scavenge free radicals. According to this review, the main 
structural requirements for this antioxidant activity are: the 2,3-olefinic bond in conjugation 
with 4-keto functional group in C ring; the catechol moiety in B ring and the hydroxyl group 
at C-5 (Figure 22) 81.  
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Major structural features for radical scavenging activity of flavones (adapted 81). 
 
 
In 2010, Hyun et al. studied the relationship between the number of hydroxyl groups 
on the flavone scaffold and its ability to scavenge free radicals. The researchers found that 
the increase of the number of hydroxyl groups is associated to the increase of the radical 
scavenging activity, being this effect particularly enhanced if two or more adjacent hydroxyl 
groups are present in the flavone nucleus. Therefore, 7,3’,4’,5’-tetrahydroxyflavone (53) 
was the most potent DPPH scavenger among the tested compounds (Figure 23) 83.  
A recent study performed by Treesuwan et al. (2015), in order to elucidate the 
importance of the hydroxyl groups on the antioxidant activity of flavones, confirmed the 
requirements demonstrated by Hyun et al. 84. 
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Figure 23. Structure of compound 53. 
 
 
Flavones also act as antioxidant agents by chelating metal ions (Fe2+ and Cu2+). The 
interactions of flavones with these catalytically active metals play an important role, because 
they prevent the formation of oxidizing species and reactive hydroxyl radicals that can be 
generated through Fenton reactions 81. In this framework, several studies indicated that the 
association between the hydroxyl group at C-5 (A ring) and the 4-keto group, as well as the 
presence of ortho-hydroxyl groups are important roles for flavone chelating activity (Figure 
24) 31,81.  
 
 
 
 
 
 
 
 
 
Figure 24. Possible sites for chelating metal ions on flavones (adapted 31). 
 
 
Another mode of antioxidant action of flavones is through inhibiting enzymes 
responsible for the production of RNS and ROS, such as inducible nitric oxide synthase 
(iNOS) and xanthine oxidase. In fact, some flavones like luteolin (54) and apigenin (55) 
(Figure 25) can inhibit iNOS 85-87. In addition, luteolin proved to be a potent inhibitor of 
xanthine oxidase 31,81. In 1997, Rastelli et al. reported a model for flavones-xanthine oxidase 
interaction, based on the structural similarity of flavone with substrates or inhibitors of this 
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enzyme 88. Details of this model may be found in the original article 88, as well as in two 
review articles 31,81. Besides this, other authors have proposed that the hydroxyl groups at 
C-6 and C-7 and the presence of catechol moiety or 3’,4’,5’–pyrogallol functionality on the 
flavone nucleus are important requirements for xanthine oxidase inhibition by flavones 31,89.  
 
 
 
 
 
 
 
 
 
 
 
 
4.3. Xanthone and flavone derivatives with dual activity 
 
 
It is known that many factors are involved in the etiology of AD. Thus, the ideal 
therapy for this disease probably will include the administration of drugs that can act by 
multiple mechanisms, including AChE and BuChE inhibition and antioxidant activity 4,34. 
As previous described, in the context of AD, xanthones and flavones can show 
various biological activities, such as ROS scavenging, and MAO and AChE inhibitory 
activities. Consequently, in recent years a great deal of effort has been devoted to find multi-
target xanthone and flavone derivatives which can be used to treat AD 37,38. In addition to 
AChE, BuChE is described as a pseudocholinesterase, since this enzyme distributed in the 
nervous system and plasma, can hydrolyze several choline esters, such as acetylcholine 
and butyrylcholine 90. Recently, researchers have found that patients with AD have high 
level of this enzyme, that could also be responsible for the lower levels of acetylcholine 
associated with AD. Thus, BuChE may also be used as a target for the treatment of AD and 
xanthones that are capable of inhibiting AChE and BuChE simultaneously, can act like anti-
Alzheimer multipotent agents 90. 
Among the xanthone and flavone derivatives that had been described as AChE 
inhibitors in subchapter 4.1. some had also been reported as BuChE inhibitors. For 
Figure 25. Structures of luteolin (54) and apigenin (55). 
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example, xanthones 1-10 (Table 1) synthesized and tested by Degen et al. (1999) were 
able to inhibit both enzymes 54. Among the xanthostigmine analogues synthesized by Piazzi 
et al. (2007), compounds 21, 22, 31 and 34 (Table 3) were the most active xanthones 
against AChE and BuChE 56. Moreover, Quin et al. (2013) evaluated the activity of the 
synthesized xanthonic derivatives against AChE and BuChE. Among the various 
compounds, xanthone 38 (Figure 15) showed the highest inhibitory activity against both 
enzymes 34. In addition to xanthones previously referred, flavones 69, 70, apigenin (55), 
kuwanon C (67) and morusin (68) were also described as AChE and BuChE inhibitors 
(Table 6) 44,62,91.  
Xanthone and flavone derivatives can also be considered as multitarget agents for 
AD not also for their activity as AChE and BuChE inhibitors but also by other mechanisms, 
namely those listed in Table 6. 
 
 
Table 6. Xanthone and flavone derivatives with dual or multitarget activity.  
Compounds 
Xanthone Derivatives 
Dual or Multitarget Activity 
 
 
 
 
AChE and BuChE inhibitor 54 
 
 
 
 
 
 
AChE and BuChE inhibitor 54 
 
 
 
 
AChE and BuChE inhibitor 54 
 
 
 
 
 
 
 
AChE and BuChE inhibitor 54 
 
 
 
 
 
 
Table 6 (continuation) 
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Compounds  
Xanthone Derivatives 
Dual or Multitarget Activity 
 
 
 
 
 
 
 
AChE and BuChE inhibitor 54 
 
 
 
 
 
AChE and BuChE inhibitor 54 
 
 
 
 
 
AChE and BuChE inhibitor 54 
 
 
 
 
 
AChE and BuChE inhibitor 54 
 
 
 
 
 
 
 
 
 
AChE and BuChE inhibitor 54 
 
 
 
 
AChE and BuChE inhibitor 54 
 
 
 
 
 
 
 
 
Table 6 (continuation) 
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Compounds 
Xanthone Derivatives 
Dual or Multitarget Activity 
 
 
 
 
AChE and BuChE inhibitor 56 
 
 
 
 
AChE and BuChE inhibitor 56 
 
 
 
 
AChE and BuChE inhibitor 56 
 
 
 
 
AChE and BuChE inhibitor 56 
 
 
 
 
MAO and AChE inhibitor 42 
 
 
 
 
 
 
 
 
 
 
 
AChE inhibitor 92 and antioxidant activity 
(hydroxyl, superoxide anion and DPPH 
radicals  scavenging) 61,93 
 
 
 
 
 
 
Table 6 (continuation) 
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Compounds 
Xanthone Derivatives 
     Dual or Multitarget Activity 
 
 
 
 
 
 
AChE inhibitor 34,75 and antioxidant activity 
(superoxide anion, peroxynitrite, hydroxyl and 
DPPH radicals scavenging) 36,72,76 
 
 
 
 
 
 
 
 
 
 
MAO inhibitor and antioxidant activity (DPPH 
radical scavenging) 37 
 
 
 
 
 
 
MAO inhibitor and antioxidant activity (DPPH 
radical scavenging) 37 
             
 
 
 
 
 
MAO and AChE inhibitor 38 
 
 
 
 
 
 
 
 
 
 
 
MAO and AChE inhibitor 38 
 
 
 
 
Table 6 (continuation) 
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 Compounds 
Xanthone Derivatives 
Dual or Multitarget Activity 
 
 
 
 
 
 
MAO and AChE inhibitor 38 
 
 
 
 
 
 
 
 
 
 
 
 
MAO and AChE inhibitor 41 
 
 
 
 
 
 
MAO and AChE inhibitor 41 
 
 
 
 
 
 
 
MAO and AChE inhibitor  41 
Table 6 (continuation) 
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Compounds 
Xanthone Derivatives 
Dual or Multitarget Activity 
 
 
 
 
 
AChE inhibitor 94 and antioxidant activity 
(superoxide 
anion, DPPH radical and hydrogen peroxide  
scavenging; cytochrome c reduction; 
protection against lipid peroxidation, oxidation 
of proteins and DNA fragmentation) 95-97 
 
 
Flavone Derivatives 
 
 
 
 
 
 
AChE 55 and MAO inhibitor 98 and antioxidant 
activity (nitric oxide, hydrogen peroxide, 
superoxide anion, peroxynitrite, DPPH and 
ABTS radicals scavenging; metal chelating 
activity; prevention of lipid peroxidation) 85,99-
101 
 
 
 
 
 
 
 
 
 
AChE 55, BuChE 91 and MAO inhibitor 43 and 
antioxidant activity (nitric oxide, superoxide 
anion, peroxynitrite and hydroxyl radicals 
scavenging; metal chelating activity; 
prevention of LDL oxidation and inhibition of 
iNOS) 85,102-106 
 
 
 
 
 
 
 
 
 
AChE inhibitor 107, anti-Aβ aggregation effect 
108 and antioxidant activity (nitric oxide, 
superoxide anion, hydrogen peroxide, 
peroxynitrite, hydroxyl and DPPH radicals 
scavenging; metal chelating activity; 
prevention of lipid peroxidation; inhibition of 
xanthine oxidase) 52,109-112  
 
 
 
 
 
 
Table 6 (continuation) 
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Compounds 
Flavone Derivatives 
Dual or Multitarget Activity 
 
 
 
 
AChE 44 and MAO inhibitor 113, anti-Aβ 
aggregation effect 113 and antioxidant activity 
(nitric oxide, hydrogen peroxide, superoxide 
anion, hydroxyl and DPPH radicals 
scavenging) 114-116 
 
 
 
 
 
 
AChE 44 and BuChE 91 inhibitor and 
antioxidant activity (nitric oxide and DPPH and 
ABTS radicals scavenging; inhibition of iNOS) 
117-119 
 
 
 
 
 
 
 
 
 
AChE  44 and BuChE 91 inhibitor and 
antioxidant activity (nitric oxide, superoxide 
anion and DPPH and ABTS radicals 
scavenging; inhibition of iNOS) 117-120 
 
 
 
 
 
 
AChE and BuChE inhibitor 62 
 
 
 
 
 
 
 
 
 
Table 6 (continuation) 
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Compounds 
Flavone Derivatives 
Dual or Multitarget Activity 
 
 
 
 
AChE and BuChE inhibitor 62 
 
 
As can been seen in Table 6, some xanthones can inhibit both AChE and MAO 
enzymes (compounds 36 and 58-63). Flavones luteolin (54), apigenin (55) and scutellarin 
(66) simultaneously exhibit anticholinesterase, antioxidant and MAO inhibitory activities.  
Over the years, it has been found other xanthone and flavone derivatives with dual 
antioxidant and anticholinesterase activities (compounds 37, 46, 54, 55, 64-68). 
Additionally, baicalein (65) and scutellarin (66) had anti-Aβ aggregation effect, as well as 
antioxidant and anticholinesterase activities. These xanthones and flavones due to their 
biological activities can also be considered as multipotent agents against AD. 
 
 
Table 6 (continuation) 
Table 6 (continuation) 
  
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER II 
 
AIMS AND OVERVIEW 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  CHAPTER II. Aims and Overview 
42 
 
The main purpose of this dissertation was to obtain xanthone and flavone derivatives 
as dual agents (anticholinesterase and antioxidants) with potential in treatment for AD. 
Inspired by the potential of natural hydroxylated xanthones and flavones as 
antioxidant agents and that Mannich base analogues of these scaffolds can enhance and/or 
provide the anticholinesterase activity, like already described above, we aimed to 
synthesize bioactive Mannich bases of hydroxylated xanthones and flavones, using natural 
products as substrates, either by molecular modification or total synthesis. To accomplish 
this goal, one natural xanthone and flavone were selected as building blocks: 1,3,8-
trihydroxyxanthone (ICX1) and baicalein (B) (Figure 26). 
 
  
  
 
 
 
 
 
1,3,8-Trihydroxyxanthone (ICX1) and baicalein (B) were chosen as building blocks, 
since the natural hydroxylated xanthones and flavones have already demonstrated to have 
antioxidant activity 30,36. Many studies showed that these natural compounds are powerful 
antioxidants against free radicals and ROS 38,39. These species when generated in excess 
can damage the biomolecules and they are, therefore involved in the etiology of several 
diseases such as AD 44. Particularly, several studies have shown that baicalein (B), isolated 
from different species of Scutellaria (examples: Scutellaria baicalensis; Scutellaria rivularis; 
Scutellaria lateriflora) 121-123, has antioxidant activity by scavenging ROS and RNS and 
chelating metal ions like iron and copper 30,112,122,124. 1,3,8-Trihydroxyxanthone (ICX1), 
isolated from Garcinia cantleyana var. cantleyana 125 was able to protect LDL from oxidation 
induced by Cu2+ and to inhibit the transition metal-induced production of free radicals by 
chelating Cu2+ 125.  
Once more, the choice for these building blocks was motivated by the facts that 
baicalein (B) has also demonstrated the ability to inhibit AChE 44,107 and that a series of 
xanthone Mannich base derivatives have been described as promising anticholinesterase 
agents 34.  
 
Figure 26. Building blocks used for the synthesis of a small library of Mannich bases. 
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These evidences prompt us to consider 1,3,8-trihydroxyxanthone (ICX1) and 
baicalein (B) as interesting building blocks for the design and synthesis of a small library of 
Mannich base derivatives with potential dual mode of action (antioxidant and AChEI) for 
AD.  
 
Other aims of this research work were: 
 
- to apply classical methodologies for the total synthesis of 1,3,8-trihydroxyxanthone 
(ICX1), namely GSS and Eaton’s reactions; 
- to obtain new compounds with promising dual mode of action for AD; 
- to elucidate the structure of the obtained derivatives through several spectroscopic 
techniques, namely IR and NMR (1H, 13C, HSQC and HMBC); 
- to evaluate the antioxidant and AChE inhibitory activities of the synthesized Mannich 
base derivatives, as well as the activity of a small library of other structure related 
aminoxanthone derivatives previously synthesized in our research group;  
- to perform molecular docking studies of the most active compound with AChE. 
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1. Xanthonic derivatives 
 
 
1.1. Introduction 
 
 
1.1.1. Synthesis of xanthones: general methodologies 
 
 
The natural xanthones have a variety of substitution patterns that lead to the 
diversity of biological/pharmacological activities attributed to this class of secondary 
metabolites (privileged structures). However, their biosynthetic pathways can be considered 
as limiting factor for structural variations in natural xanthones. Thus, in recent years, 
strategies for synthesis of xanthones have received much attention in order to obtain novel 
xanthonic derivatives with important biological/pharmacological activities 126.  
Michael and Kostanecki (1883 and 1891) developed the first method for the 
synthesis of xanthones, which is based on the distillation of a mixture of o-hydroxybenzoic 
acid and acetic anhydride 127.  
Over the years alternative methods were developed being three of them widely 
used: synthesis of xanthones in one step; the synthesis of xanthones via benzophenone 
and through a diaryl ether 126,128. 
The Grover, Shah and Shah (GSS) reaction is a methodology that allows obtaining 
the xanthone scaffold from a single step. In this strategy, the xanthone is obtained by the 
reaction of a salicylic acid derivative with a polyphenolic compound catalyzed by zinc 
chloride / phosphoryl chloride, an acid catalyst (Figure 27) 129. 
 
 
 
 
 
 
Figure 27. Synthesis of simple xanthones by GSS reaction (adapted 126). 
 
 
More recently, other methods that involve the synthesis of xanthone from a single 
step were created 128. In 2005, Zhao et al. developed, for the first time, a synthesis 
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methodology that involves the reaction of salicylate esters with an aryne intermediary 
(Figure 28) 130. The choice of the solvent in this strategy is a very important factor and it 
has been reported that tetrahydrofuran is the most suitable solvent for this method, since it 
allows obtaining the xanthone with high selectivity and high yields 128,130. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Synthesis of simple xanthones using salicylates and trimethylsilylaryl triflates (adapted 
128). 
 
 
In 2010, Dubrovskiy and Larock proposed a change to this methodology, where 
xanthones would be produced by the reaction of o-halobenzoic acids with aryne 
intermediates (Figure 29) 131. 
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Figure 29. Synthesis of simple xanthones from the reaction of o-halobenzoic acids with aryne 
intermediates (adapted 128). 
 
 
Other methodology allowing the synthesis of xanthones in one step was developed 
by Wang et al. in 2009. This method of synthesis involves the reaction of salicylaldehyde 
and 1,2-dibromobenzene derivatives, where the annulations are catalyzed via palladium 
(Figure 30) 132.  
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Figure 30. Synthesis of simple xanthones by palladium-catalyzed annulations (adapted 128). 
 
 
Other strategy in the context of one-step synthesis of xanthones was developed by 
Hu et al. in 2012. These researchers used phenols and various aryl aldehydes as starting 
materials and CuCl2 as a catalyst in the presence of triphenylphosphine (Figure 31). 
Although it was obtained xanthones with high yields, this methodology has some limitations, 
including the fact that the phenols have to be activated and the reaction times are very high 
133.  
 
 
 
 
 
 
 
Figure 31. Synthesis of xanthones by ortho-acylation of phenols with 2-substituted aldehydes 
(adapted 133). 
 
 
In fact, the use of copper catalysts in reactions in organic chemistry has associated 
economic advantages, but also allows more “green” reactions in the context of green 
chemistry. Therefore, in recent years, it has been tried to develop efficient copper-based 
catalysts which may be used in various reactions 134. 
In this framework and in order to improve the methodology developed by Hu et al., 
Menendez et al., in 2014, established the synthesis of xanthones based on the reaction 
between ortho-substituted benzaldehydes and phenols, catalyzed by magnetic 
nanocatalyst that consists of CuNPs on silica coated maghemite (Figure 32) 134. With this 
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synthetic strategy and with these catalysts, it was possible to obtain xanthones with high 
yields and overcome the limitations associated with more classic methodologies 134. 
 
 
 
 
 
 
 
Figure 32. Synthesis of xanthones by reaction between ortho-substituted benzaldehydes and 
phenols, catalyzed by nanocatalysts (CuNPs) (adapted 134). 
 
 
Additionally, in 2015, Genovese et al., proposed the synthesis of xanthones under 
microwave conditions and using ytterbium triflate as acid catalyst 135. In this approach, 
substituted 2-hydroxybenzoic acids react with phenols in the presence of Yb(OTf)3 hydrate 
by microwave irradiation to afford the xanthone in high yields (Figure 33) 135. 
 
 
 
 
 
 
 
 
Figure 33. Synthesis of xanthones under microwave conditions promoted by ytterbium triflate 
(adapted 135). 
 
 
In addition to these synthetic strategies that involve a single step, multi-step 
methodologies were created 128. Among the various strategies developed, one that is 
frequently used is the benzophenone route. This route, basically involves the synthesis of 
benzophenone followed by its cyclization 126. Several strategies to synthesize 
benzophenone intermediate and its cyclization can be seen in Figure 34.  
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Figure 34. Several alternatives for the synthesis of xanthones through benzophenone route (adapted 
128). 
 
 
Among all these strategies that can be used for the synthesis of benzophenone, the 
most common is the Friedel-Crafts acylation of a phenol or a protected phenol-derivative in 
presence of an acyl chloride, catalyzed by aluminum chloride (Figure 35) 136.  
 
 
 
 
 
 
Figure 35. Synthesis of the benzophenone through a Friedel-Crafts acylation (adapted 128). 
 
 
Another methodology for the synthesis of the xanthone scaffold is that which follows 
the diaryl ether route. This route that uses diaryl ether as key intermediate, also involves 
two main steps: the synthesis of diaryl ether and subsequent cyclization. All strategies for 
synthesis and cyclization of the intermediate are summarized in Figure 36 126,128. 
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Figure 36. Synthesis of xanthones through diaryl ether route (adapted 128). 
 
 
All the synthetic strategies described so far involve basically two aryl derivatives as 
building blocks, and the xanthone scaffold was obtained by the formation of an ether and 
ketone linkage 128. However, other strategies using chromen-4-ones as building blocks were 
developed. This strategy has the advantage of allowing the synthesis of xanthones with 
more complex substitution patterns. Depending on the substituents at positions 2 and 3 of 
the chromen-4-ones, different reactions can be used to obtain xanthone (Figure 37) 128. 
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Figure 37. Synthesis of xanthones from chromen-4-one and some examples of xanthone obtained 
by this route (adapted 128). 
 
 
El-Desoky et al., in 2014, reported the synthesis of xanthone nucleus through 
domino reactions of 3-vinylchromone 137. Domino reactions are a synthetic strategy that 
consist of two or more bond- forming reactions in which the subsequent transformation 
result as a consequence of the functionality obtained in the previous step, affording the 
synthesis of complex molecules 137. Particularly, in the methodology developed by these 
researchers, various heterocyclic nuclei, including xanthone, were obtained using a 
domino protocol starting from 3-vinylchromone (Figure 38) 137.  
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Figure 38. Synthesis of xanthone via domino reactions (adapted 137). 
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1.2. Results and discussion 
 
 
1.2.1. Synthesis  
 
 
1.2.1.1. 1,3,8- Trihydroxyxanthone (ICX1) 
 
 
In recent years, a large number of methodologies for the synthesis of simple 
oxygenated xanthonic derivatives have been developed 128.  Among the various synthetic 
methodologies that are available, in this work, the building block 1,3,8-trihydroxyxanthone 
(ICX1) was obtained by one-pot  synthesis using two different strategies: Eaton’s reaction 
and GSS reaction.  
In accordance with literature 126 and the experience of our research group, the 
synthesis of hydroxylated xanthones by GSS demands a difficult work up, when compared 
with the Eaton’s reaction. Therefore, ICX1 was firstly synthesized by Eaton’s reaction. 
In the Eaton’s reaction, ICX1 was obtained by the condensation of 2,6-
dihydroxybenzoic acid with phloroglucinol in the presence of a mixture of phosphorus 
pentoxide - methanesulfonic acid (Eaton’s reagent) as condensing agent (Figure 39). 
 
 
 
 
 
 
 
 
Figure 39. General conditions for the synthesis of 1,3,8-trihydroxyxanthone (ICX1) by Eaton's 
reaction. 
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The yield obtained in this reaction was very low (2.07%), being this mainly due to 
the formation of a by-product with a similar retention factor, making the purification of the 
desired xanthone by flash column chromatography or thin layer chromatography (TLC) very 
difficult. 
Therefore, ICX1 was also synthesized by GSS. In this reaction, ICX1 was obtained 
by the condensation of 2,6-dihydroxybenzoic acid with phloroglucinol in the presence of 
zinc chloride in phosphorus oxychloride, instead of Eaton’s reagent (Figure 40). Although 
this condensation agent has been shown to be efficient for the synthesis of hydroxylated 
xanthones, this synthetic methodology has some limitations and low yields 126,128. Taking 
these into account, some experimental modifications to the classic GSS reaction were 
performed including the stepwise addition of reactants and the use of microwave assisted 
organic synthesis (MAOS), instead of conventional thermal heating (classical synthesis). 
Particularly, in the original GSS methodology, a mixture of an hydroxybenzoic acid, a 
phenol, fused zinc chloride and phosphorus oxychloride was heated together on a water 
bath. Instead, in the GSS reaction modified by our research group, firstly a mixture of fused 
zinc chloride and phosphorus oxychloride was irradiated by MW at 400 W for 10 min at 60 
ºC; then, the hydroxybenzoic acid was added and the mixture was subjected to MW 
irradiation at 400 W for 10 min at 60 ºC and finally, the appropriated phenol was added and 
the mixture was once more submitted to MW at 400 W for 60 min at 60 ºC. The synthetic 
route, the reaction conditions and the yield for ICX1 are shown in Figure 40. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40. General conditions for the synthesis of 1,3,8-trihydroxyxanthone (ICX1) by GSS reaction. 
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According to Figure 40, the yield of this reaction was very low (2.38%). These results 
were not expected, since this GSS methodology had been applied in this research group 
for the synthesis of other hydroxylated xanthones with higher yields 138.  
This low yield could be explained by the fact that this reaction has been incomplete, 
and more than one product have been formed, making the purification steps quite 
complicated and time consuming. Particularly, an amount of 2,6-dihydroxybenzoic acid that 
remained in the reaction mixture proved to be extremely difficult to remove by a simple flash 
column chromatography. Therefore, to optimize the purification process, prior to column 
chromatography an extraction with a saturated solution of NaHCO3 5% was performed in 
order to eliminate 2,6-dihydroxybenzoic acid.  
Table 7 summarizes the reaction conditions and purification processes used for the 
synthesis of 1,3,8-trihydroxyxanthone (ICX1) by the two different reactions. In general, both 
approaches showed short reaction times (Eaton’s reaction: 1 h 30 min; modified GSS 
reaction by MW: 1 h 20 min) and low yields. Although purification of ICX1 in both reactions 
was time consuming, this process was more complex in the GSS reaction. In fact, in this 
methodology, three different procedures had been performed: extraction with CH2Cl2 in 
order to remove a brown slimy material; extraction with saturated solution of NaHCO3 5% 
to eliminate benzoic acid and a flash column chromatography to get ICX1. In contrast, in 
Eaton’s reaction, ICX1 was only obtained using flash chromatography as purification 
method. In conclusion, according to these results, Eaton’s reaction seems to be more 
suitable than GSS for the synthesis of ICX1, because it was a cleaner approach, which 
required less purification procedures. 
 
Table 7. Reaction conditions and purification processes for the synthesis of 1,3,8-trihydroxyxanthone 
(ICX1) by Eaton's reaction and Modified GSS reaction assisted by MW.  
 Eaton’s reaction Modified GSS reaction 
assisted by MW 
 
 
Reaction Conditions 
a: P2O5/CH3SO3H, 90 ºC, 30 min (Eaton's 
reagent formation) 
b: 2,6- dihydroxybenzoic 
acid/phloroglucinol, 80 ºC, 1 h 
a: ZnCl2, POCl3, MW (400W), 60 ºC, 10 
min 
b: 2,6- dihydroxybenzoic acid, MW 
(400W), 60 ºC, 10 min 
c: phloroglucinol, MW (400W), 60 ºC, 60 
min 
 
Purification Processes 
 
flash column chromatography. 
extraction with CH2Cl2; 
extraction with saturated solution of 
NaHCO3 5%; 
flash column chromatography. 
Yields 2.07% 2.38% 
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1.2.1.2. Amino derivatives of 1,3,8-trihydroxyxanthone  
 
 
The 1,3,8-trihydroxyxanthone ICX1 was used as building block for the synthesis of 
the correspondent amino derivatives, by the Mannich reaction.  
The Mannich reaction who accidentally took place for the first time in 1912, is 
nowadays one of the most important strategies that is used in organic chemistry for the 
aminomethylation of compounds and formation of new C-C bonds. Over the years, its 
products (Mannich bases) have shown a variety of biological activities, and therefore this 
synthetic approach has been widely used in the medicinal pharmaceutical chemistry for 
drug design 139,140. 
Basically, the classic Mannich reaction consists of a three-component  
condensation, which involves several substrates having at least one active hydrogen atom, 
an aldehyde (usually formaldehyde) and an amine reagent to give a class of compounds 
called Mannich bases (Figure 41). 
 
 
 
 
 
 
 
 
Figure 41. General representation of Mannich reaction (adapted 140). 
 
 
The reaction conditions range according to the substrate (may belong to a diverse 
class of compounds), the amine and the aldehyde that are used 141. Thus, there are a large 
number of combinations amine / substrate which can be used in this reaction, being one of 
the reasons for the wide applicability of this synthetic strategy 140-142. Additionally, in the 
Mannich reaction there are three different procedures for the addition of the reactants 141. 
The most common procedure consists of mixing all the chemical species involved in the 
reaction, while the second approach involves first the reaction of the amine with the 
aldehyde, and then the addition of substrate 141. Alternatively, in some cases, it is performed 
the condensation of substrate and aldehyde, and then the methylated derivative formed is 
isolated and reacted with the respective amine 141. 
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Particularly, in our work, for the aminomethylation of ICX1, diethylamine was allowed 
to react with formaldehyde in methanol for 1 hour and then a solution of ICX1 was added to 
the reaction mixture (Figure 42). 
 
 
 
 
 
 
 
Despite being used the same reaction conditions reported in literature for the 
phenolic Mannich reactions 141, and particularly for hydroxylated xanthones 34, this synthetic 
approach failed to produce the desired amino derivative of ICX1. More specifically, it has 
been found that this Mannich reaction was not complete and led to the formation of a wide 
variety of by-products which made impossible to obtain the desired aminoxanthonic 
derivative.  
In order to afford this derivative, successive attempts of purification were carried out. 
Firstly, crystallization was performed with a mixture of chloroform / methanol, but it did not 
result. Then, we made a flash column chromatography using chloroform / acetone as eluent. 
No pure fractions were obtained, and therefore, the fractions that contained the same 
chromatographic profile were joined. Subsequently, flash column chromatography and 
preparative TLC were performed for the fractions with positive revelation with ferric chloride. 
Although all these purification steps have been performed, the desired amino derivative of 
ICX1 was not isolated. 
Despite these results not being expected, they are supported by the literature. A 
major disadvantage of Mannich reactions is the formation of by-products that could cause 
difficulties in the purification of the final product, being necessary to develop more specific 
protocols 141,142. In fact, several secondary reactions have been identified as the main routes 
which may be involved in the production of undesired by-products in Mannich reactions 141. 
These main pathways are shown in Figure 43. 
 
Figure 42. General conditions for the synthesis of amino derivative of 1,3,8-trihydroxyxanthone 
(ICX1) by Mannich reaction. 
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Figure 43. By-products accompanying Mannich reaction (adapted 141). 
 
 
According to this review, the pathway a) occurs when the amine used as reactant is 
very stable and the substrate is poorly reactive, resulting in the formation of by-products 
that derive exclusively from the amine reactant. The route b) shows a typical reaction that 
results in a further aminomethylation, which leads to the formation of a Mannich base. This 
Mannich base may behave as an amine or substrate, depending on the functionality present 
in the starting materials of the reaction. The pathway c) represents a situation in which can 
occur a deaminomethylation of the Mannich base and it may be generated dimers or 
polymers as by-products. Finnaly, the route d) shows the synthesis of methylene-bis-
derivatives of substract as by-products of some Mannich reactions 141. 
Additionally, our results may be also explained by the fact that the aminomethylation 
have not only occurred at C-2. Taking into account the structure of building block ICX1, it 
can be verified that this is the most nucleophilic aromatic position, but C-4 and C-7 are also 
activated and, consequently, the aminomethylation could happen at those positions, 
generating other amino derivatives of ICX1. Thus, is possible that this may have also 
contributed to the formation of more by-products. 
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1.2.1.3. Methylated derivative of 1,3,8-trihydroxyxanthone (ICX2) 
 
 
The synthetic approach used for the synthesis of methylated derivative ICX2 was 
based on the reaction of 1,3,8-trihydroxyxanthone (ICX1) with methyl iodide in presence of 
anhydrous potassium carbonate and anhydrous acetone 34. The reaction conditions and the 
results obtained in the synthesis of ICX2 are present in Figure 44. 
 
 
 
 
 
 
 
Figure 44. General conditions for the synthesis of methylated derivative of 1,3,8-trihydroxyxanthone 
(ICX2).  
 
 
This synthetic strategy demonstrated to be efficient for the synthesis of ICX2, being 
this derivative obtained in high yield (74%). In addition, as expected, the obtained results 
indicated that O-methylation of ICX1 occurs only at the hydroxyl group on the position 3, 
since a weak base was used in this reaction.  
 
 
1.2.1.4. Amino derivative of 1,8-dihydroxy-3-methoxyxanthone (ICX2a) 
 
 
The methylated derivative of 1,3,8-trihydroxyxanthone (ICX2) was used as building 
block for the synthesis of aminoxanthone ICX2a by the Mannich reaction. The general 
experimental conditions and its results are indicated in Figure 45. 
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The synthetic conditions were quite different from those used for the synthesis of 
amino derivatives of ICX1 (section 1.2.1.2.). In accordance with the procedure described by 
Qin et al. (2013) for the synthesis of amino derivatives of 1-hydroxy-3-methoxyxanthone, in 
this Mannich reaction, instead of methanol as solvent, acetic acid was used as acid catalyst 
34. These acidic conditions are often used in this kind of reactions in order to favor the 
reaction, by facilitating the formation of iminium cation and / or to improve the stability of the 
product formed 141.  
Even under these conditions, the reaction time was high (6 days) and the yield for 
ICX2a was low (6.29%). This low yield could be justified by the fact of this reaction has been 
incomplete and its work-up has been difficult and time-consuming. Particularly, the 
purification of ICX2a by flash column chromatography was difficult because some by-
products formed in this reaction had a similar polarity to the desired compound and, 
consequently, were isolated with ICX2a.  
 
 
 
 
 
 
 
 
 
Figure 45. General conditions for the synthesis of amino derivative of 1,8-dihydroxy-3-
methoxyxanthone (ICX2a) by Mannich reaction. 
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1.2.2. Evaluation of xanthones purity 
 
 
The purity of each compound was determined by HPLC-DAD, using a C18 stationary 
phase and a mixture of methanol:water:acetic acid (70:30:1 v/v/v) as mobile phase, and the 
results obtained are presented in Table 8. 
 
 
Table 8. Retention time and purity of ICX1, ICX2 and ICX2a. 
Compound Retention time (min) Purity (%) 
ICX1 12.2 97.4 
ICX2 27.6 98.9 
ICX2a 2.8 99.5 
 
 
According to Table 8, it can be verified that all synthesized compounds show a purity 
higher than 95% by HPLC-DAD method. 
 
 
1.2.3. Structure elucidation 
 
 
The structure elucidation of all xanthone derivatives was established on the basis of 
IR and NMR techniques. 13C NMR assignments were determined by heteronuclear single 
quantum coherence (HSQC) and heteronuclear multiple bond correlation (HMBC) 
experiments. 
 
The IR data of 1,3,8-trihydroxyxanthone (ICX1) and its derivatives (ICX2 and ICX2a) 
were in accordance with the performed molecular modification (Table 9). The IR spectra of 
compounds ICX1, ICX2 and ICX2a showed the presence of absorption bands 
corresponding to the C=O (1663-1653 cm-1), aromatic C=C (1605-1470 cm-1) and C-O 
(1296-1293 cm-1). The presence of methyl groups in the derivatives ICX2 and ICX2a was 
suggested by the observation of bands at 2959-2852 cm-1 characteristic of aliphatic C-H. As 
the precursor (ICX1), for derivatives ICX2 and ICX2a, a large band of stretching vibration 
at 3600-3400 cm-1 (hydroxyl groups) was visualized, revealing that the methylation did not 
occur at all hydroxyl groups of ICX1. Additionally, the presence of an aliphatic amine in the 
  CHAPTER III. Synthesis 
63 
 
xanthone ICX2a was suggested by the observation of a stretching vibration band at 1230 
cm-1. 
 
 
            Table 9. IR data of 1,3,8-trihydroxyxanthone (ICX1) and its derivatives ICX2 and ICX2a. 
Groups  (cm-1) 
ICX1 ICX2 ICX2a 
OH 3500-3400 3500-3400 3600-3400 
Aliphatic  
C-H 
– 2959 
2925 
2852 
2923 
2853 
C=O 1663 1662 1653 
Aromatic  
C=C 
1601 
1565 
1514 
1483 
1603 
1568 
1505 
1470 
1605 
1558 
1539 
1490 
C-O 1293 1294 1296 
C-N – – 1230 
 
 
The 1H and 13C NMR data of 1,3,8-trihydroxyxanthone (ICX1) and its derivatives 
(ICX2 and ICX2a) are reported in Table 10 and Table 11. 
The 1H NMR spectra of 1,3,8-trihydroxyxanthone (ICX1) showed signals of two 
hydrogen-bonded hydroxyl group at δH 11.89 s and δH 11.81 s, revealing the presence of 
two hydroxyl groups linked to C-1 and C-8. The presence of a broad triplet at δH 7.68 (H-6) 
coupled with two double doublets at δH 7.00 (H-5) and δH 6.79 (H-7) reveals the presence 
of three aromatic protons on consecutive carbon atoms on B ring. In addition, the signals of 
two doublets at δH 6.38 (H-4) and δH 6.21 (H-2) confirmed the presence of two meta coupled 
aromatic protons in A ring. The low chemical shifts of these two doublets in comparison to 
that observed for H-5, H-6 and H-7 are in accordance to the expected for aromatic protons 
on orto/para positions to hydroxyl groups. The 13C NMR data confirmed the structure 
proposed for this compound. All spectroscopic data are in agreement with those found in 
the literature 143. 
As the precursor (ICX1), the 1H NMR spectra of derivatives ICX2 and ICX2a showed 
that both have retained the hydrogen-bonded hydroxyl group at C-1 (δH 12.09-11.99 s) and 
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C-8 (δH 12.09- 11.92 s) and three aromatic protons at δH 7.56-7.55 brt (H-6), δH 6.87- 6.86 
dd or brd  (H-5), and δH 6.78 dd or brd (H-7). For derivative ICX2, two meta coupled aromatic 
protons at δH 6.35 d (H-2) and δH 6.42 d (H-4) are also observed, confirming the presence 
of hydrogen atoms on H-2 and H-4. Instead of these two double doublets, only one singlet 
at δH 6.44 (H-4) is observed in 1H NMR of ICX2a and characteristic signals of a 
dimethylamine (δH 2.37 s; δC 44.96) attached to C-2 through a methylene bridge (δH 3.64 s; 
δC 49.97) are observed in the 1H and 13C spectra, suggesting the presence of a 2-
(dimethylamino)methyl side chain. 
The position of the methyl and dimethylaminomethyl side chains in derivatives ICX2 
and ICX2a was confirmed by the correlations found in the HMBC indicated in Figure 46. 
 
 
 
 
 
 
 
 
 
 
Table 10. 1H NMR data of 1,3,8-trihydroxyxanthone (ICX1) and its derivatives (ICX2 and ICX2a).  
 ICX1 ICX2 ICX2a 
H-1 11.89 (OH, s) 11.99 (OH, s) 12.09 (OH, s) 
H-2 6.21 (d, J =2.1) 6.35 (d, J = 2.3) ___ 
2- CH2N ___ ___ 3.64 (s) 
N(CH3)2 ___ ___ 2.37 (s) 
H-3 ___ ___ ___ 
3- OCH3 ___ 3.89 (s) 3.94 (s) 
H-4 6.38 (d, J = 2.1) 6.42 (d, J = 2.3) 6.44 (s) 
H-5 7.00 (dd, J = 8.4, 0.9) 6.87 (dd, J = 8.4, 0.8) 6.86 (brd, J = 8.3) 
H-6 7.68 (brt, J = 8.4) 7.56 (brt, J = 8.4) 7.55 (brt, J = 8.3) 
H-7 6.79 (dd, J = 8.4, 0.9) 6.78 (dd, J = 8.4, 0.8) 6.78 (brd, J = 8.3) 
H-8 11.81 (OH, s) 11.92 (OH, s) 12.09 (OH, s) 
Values in parts per million (δH). Measured in DMSO-d6 (ICX1) and CDCl3 (ICX2 and ICX2a) at 300.13 MHz. J values (Hz) are 
presented in parentheses.  
 
Figure 46. Main connectivities found in the HMBC of ICX2 and ICX2a. 
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Table 11. 13C NMR data of 1,3,8-trihydroxyxanthone (ICX1) and its derivatives (ICX2 and ICX2a).  
 ICX1 ICX2 ICX2a 
C-1 162.16 162.97 161.39 
C-2 98.70 97.41 103.5 
 
2- CH2N ___ ___ 49.97 
 
N(CH3)2 ___ 
 
___ 44.96 
C-3 167.06 167.35 165.79 
3- OCH3 ___ 55.93 56.34 
C-4 94.48 93.10 90.05 
C-4a 157.51 157.78 157.69 
C-5 107.10 106.96 107.85 
C-6 137.18 136.80 136.58 
C-7 110.60 110.89 110.90 
C-8 160.27 161.31 161.39 
C-8a 106.88 106.96 106.79 
C-9 183.26 184.63 184.33 
C-9a 101.00 102.70 102.70 
C-10a 155.49 156.14 155.96 
Values in parts per million (δC). Measured in DMSO-d6 (ICX1) and CDCl3 (ICX2 and ICX2a) at 75.47 MHz.  
Assignments were confirmed by HSQC and HMBC experiments. 
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2. Flavone derivatives 
 
 
2.1. Introduction 
 
 
2.1.1. General methodologies for the synthesis of flavones 
 
 
The natural flavones exhibit a diversity of biological activities as mentioned above. 
However, the structural diversity of flavones, and consequent their biological activities are 
limited by their biosynthetic pathways. In this context, in recent years, it has been developed 
several strategies to synthesize flavones, in order to obtain flavonic derivatives with the 
desired biological / pharmacological activities 32. 
Currently, there are several methodologies that can be used for the synthesis of 
flavones, which can be divided into two groups: one type of strategies that involves β-
diketones as penultimate intermediates and other type that uses chalcones as penultimate 
intermediate 32.  
Considering the first approach for the synthesis of flavones, the Baker-
Venkataraman rearrangement is the most used strategy, consisting in conversion of o-
hydroxyacetophenone into phenolic ester, which suffers an intramolecular Claisen 
condensation to form a β-diketone. Then, occurs the cyclization of the β-diketone to give 
the flavone scaffold Figure 47 32,144,145.   
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Figure 47. Synthesis of flavone via β-diketone intermediate (adapted 32). 
 
 
Over the years, researches tried to develop strategies for the one-step synthesis of 
flavones from β-diketones 32. In 1951, Mentzer and Pillion synthesized flavones through 
one-step process, in which a phenol reacts with β-ketoesters under conventional heating 32. 
However with this methodology, flavones were obtained in low yields 32. In order to improve 
this strategy, in 2005, Seijas et al. have proposed a one-step synthesis of flavones under 
microwave irradiation and without using solvents 146. In this methodology, phloroglucinol 
reacts with β-ketoesters under microwave conditions to afford flavones with high yields 
(Figure 48) 146. 
 
 
 
 
 
 
Figure 48. Synthesis of flavones under microwave conditions (adapted 147). 
 
 
The second strategy available for the synthesis of flavones uses chalcones as 
intermediates, which are also natural precursors of flavones. In this approach, chalcones 
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are synthesized through Claisen-Schmidt reaction of acetophenones with benzaldehydes. 
Then, chalcones can lead to flavone scaffold directly or through flavanone. The common 
method that is used to promote the cyclization of the chalcone to give the flavone is an 
oxidative ring closure with bromine and base (Figure 49) 32.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 49. Typical oxidative cyclization of 2-hydroxychalcone (adapted 32). 
 
 
Moreover, flavones can also be obtained by cross-coupling reactions. Considering 
the methodology developed by Liang et al., flavones were obtained by sequential 
carbonylative coupling of o-iodophenols with terminal acetylenes (Figure 50) 147. This 
synthetic strategy has undergone some modifications, including the use of microwave 
irradiation or the use of ionic liquids 30,32. 
 
 
 
 
 
Figure 50. Synthesis of flavones via cross coupling reactions (adapted 32). 
 
 
Another approach available for the synthesis of flavones is Wittig-type reaction 32. 
According to the methodology reported by Kumar and Bodas, firstly, the silyl ester of O-
acyl(aroyl)salicylic acids reacts with (trimethylsilyl)- methylenetriphenylphosphorane to give 
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the acylphosphorane (Figure 51) 148. Then, acylphosphorane undergoes ring closure via 
the intramolecular Wittig reaction on the ester carbonyl to afford the flavone (Figure 51) 148.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 51. Synthesis of flavones via Wittig-type reactions (adapted 148). 
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2.2. Results and discussion 
 
 
2.2.1. Synthesis 
 
 
2.2.1.1. Amino derivative of baicalein (ICB1)  
 
 
The synthetic approach used for the synthesis of the amino derivative of baicalein 
ICB1 was also a Mannich reaction type. The synthetic route, the reaction conditions and 
the results are summarized in Figure 52.  
 
 
 
 
 
 
 
 
 
 
 
 
 
In this Mannich reaction, unlike those described above, the reaction was performed 
as described by Zhang et al. (2008) for the synthesis of same compound, i. e., formaldehyde 
and dimethylamine were added to a baicalein methanolic solution. In contrast to that 
reported by Zhang et al. (2008), the 1H NMR of the crude product that was expected to be 
the desired amino derivative ICB1 revealed a mixture of compounds. Therefore, an 
additionally flash column chromatography was necessary to achieve its purification. For this 
reason, the obtained yield was relatively low (10.50%) when compared to the previously 
reported by Zhang et al. (2008) 149. 
Figure 52. General conditions for the synthesis of amino derivative of baicalein (ICB1) by Mannich 
reaction. 
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Despite this, our results show that this Mannich reaction was efficient for the 
synthesis of ICB1 and the aminomethylation occurs at the most nucleophilic aromatic 
position (C-8) of baicalein. 
 
 
2.2.2. Evaluation of the flavone purity 
 
 
The purity of baicalein amino derivative ICB1 was determined by HPLC-DAD, using 
a C18 stationary phase and a mixture of methanol:water:acetic acid (70:30:1 v/v/v) as 
mobile phase, and the results obtained are presented in Table 12. 
 
 
Table 12. Retention time and purity of ICB1. 
Compound Retention time (min) Purity (%) 
ICB1 2.6 94.3 
 
 
According to Table 12, it can be verified that ICB1 shows a purity of 94.3%.   
 
 
2.2.3. Structure elucidation 
 
 
The structure elucidation of ICB1 was established on the basis of IR and NMR 
techniques. 13C NMR assignments were determined by HSQC and HMBC experiments. 
 
The IR data of baicalein (B) and its amino derivative (ICB1) are presented in Table 
13. As the precursor, the IR spectra of ICB1 showed the presence of absorption bands 
corresponding to hydroxyl (3500-3250 cm-1), C=O (1667 cm-1), aromatic C=C (1608-1468 
cm-1) and C-O (1287 cm-1) groups. Additionally, bands at 2955 cm-1 and 2919 cm-1 
suggested the presence of alkyl groups and a band at 1247 cm-1 was in accordance to the 
presence of an aliphatic amine. 
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Table 13. IR data of baicalein (B) and its derivative ICB1. 
Groups  (cm-1) 
B ICB1 
OH 3500-3300 3500-3250 
Aliphatic 
C-H 
 
– 
2955 
2919 
C=O 1651 1667 
Aromatic 
C=C 
1609 
1573 
1498 
1462 
1608 
1572 
1536 
1468 
C-O 1287 1287 
C-N – 1247 
 
 
 
The 1H and 13C NMR data of baicalein (B) and its amino derivative (ICB1) are 
reported in Table 14 and Table 15. The NMR data for ICB1 are in agreement with literature 
150. 
The 1H NMR spectrum of derivative ICB1 showed the presence of an hydrogen-
bonded hydroxyl group at C-5 (δH 12.52 s), as well as a non-substituted B ring (H-3’,4’,5’: 
δH 7.54-7.52 m; H-2’,6’: δH 7.84-7.82 m) as the building block (B). Instead of the singlet at 
δH 6.60 s (H-8) observed for baicalein (B), characteristic signals of a dimethylamine (δH 2.45 
s; δC 44.47) attached to C-8 by a methylene bridge (δH 4.01 s; δC 55.39) are observed in 
the 1H NMR and 13C NMR spectra of ICB1. The position of this dimethylaminomethyl side 
chain in derivative ICB1 was supported by the correlations observed in the HMBC spectrum 
(Figure 53). 
 
 
 
 
 
 
 
 
 
 
 Figure 53. Main connectivities found in the HMBC of ICB1. 
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Table 14. 1H NMR data of baicalein (B) and its amino derivative (ICB1). 
 B1 ICB1 
H-3 6.64 (s) 6.63 (s) 
H-5 12.72 (OH, s) 12.52 (OH, s) 
H-6 — — 
H-7 — — 
H-8 6.60 (s) — 
N(CH3)2 — 2.45 (s) 
CH2N — 4.01 (s) 
H-2’,6’ 7.92-7.88 (m) 7.84- 7.82 (m) 
H-3’,4’,5’ 7.60-7.52 (m) 7.54-7.52 (m) 
Values in parts per million (δH). Measured in CDCl3 at 300.13 MHz.  
 
 
Table 15. 13C NMR data of baicalein (B) and its amino derivative (ICB1). 
 B1 ICB1 
C-2 163.0 162.60 
C-3 104.2 104.31 
C-4 182.0 182.53 
C-4a 104.4 105.18 
C-5 146.5 145.43 
C-6 128.7 119.78 
C-7 152.8 153.65 
C-8 93.7 98.54 
8-CH2N — 55.39 
N(CH3)2 — 44.47 
C-8a 150.0 147.17 
C-1’ 130.9 131.43 
C-2’,6’ 125.6 126.02 
C-3’,5’ 128.5 129.10 
C-4’ 131.1 132.05 
Values in parts per million (δC). Measured in CDCl3 at 75.47 MHz.  
Assignments were confirmed by HSQC and HMBC experiments. 
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3. Experimental 
 
 
3.1. General Methods 
 
 
All the reagents and solvents were purchased from Sigma Aldrich and were used 
without further purification. Solvents were evapored using rotary evaporator under reduced 
pressure (Buchi Waterchath B-480). 
MW reactions were performed using a glassware setup for atmospheric-pressure 
reactions and a 100 mL reactor (internal reaction temperature measurements with a fiber-
optic probe sensor) and were carried out using an Ethos MicroSYNTH 1600 Microwave 
Labstation from Milestone. 
All reactions were monitored by TLC carried out on precoated plates (silica gel, 60 
F 254 Merck) with 0.2 mm of thickness. The visualization of the chromatograms was under 
UV light at 254 and 365 nm. 
The purifications of compounds were performed by flash column chromatography 
using Macherey-Nagel silica gel 60 (0.04-0.063 mm) or by preparative TLC using Merck 
silica gel 60 (GF254) plates.  
Melting points were obtained in a Köfler microscope and are uncorrected. 
IR spectra were measured on a KBr microplate in a FTIR spectrometer Nicolet iS10 
from Thermo Scientific with Smart OMNI-Transmisson accessory (Software OMNIC 8.3). 
1H and 13C NMR spectra were performed in the Departamento de Química, 
Universidade de Aveiro, and were taken in CDCl3 (Deutero GmbH) at r.t. or DMSO-d6 
(Deutero GmbH) at r.t., on Bruker Avance 300 instruments (300.13 MHz for 1H and 75.47 
MHz for 13C). 
Analytical HPLC-DAD analyses were performed on a SpectraSYSTEM (Thermo 
Fisher Scientific, Inc, USA) equipped with a P4000 pump, an AS3000 autosampler and a 
diode array detector UV8000. The separation was carried out on a 250 x 4.6 mm i.d. 
FortisBIO C18 (5 µm) (FortisTM Technologies Ltd, Cheshire, UK). ChromQuest 5.0 (version 
3.2.1) software (Thermo Fisher Scientific Inc.) managed chromatographic data. Methanol 
(HPLC grade) was obtained from Carlo Erba Reagents, (Val de Reuil, Italy), acetic acid 
(HPLC grade) was obtained from Romil Pure Chemistry (Cambridge, UK) and HPLC grade 
water (Simplicity® UV Ultrapure Water System, Millipore Corporation, USA). Prior to use, 
mobile phase solvents were degassed in an ultrasonic bath for 15 min. 
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3.2. Synthesis of xanthone derivatives 
 
 
3.2.1. Synthesis of 1,3,8-trihydroxyxanthone (ICX1) 
 
 
Method A: Eaton’s reaction 
A mixture of phosphorus pentoxide (1.00 g, 3.50 mmol) and methanesulfonic acid 
(15 mL) was heated on a steam bath (90 °C) until a clear solution was obtained (30 
minutes). Then, a mixture of phoroglucinol (0.38 g, 3 mmol) and 2,6-dihydroxybenzoic acid 
(0.46 g, 3 mmol) was added to the reaction mixture. This mixture was stirred at reflux (80 
˚C) for 1 h and the progress of the reaction was monitored by TLC. Then, the resulting 
mixture was slowly poured into crushed ice and allowed to stand overnight in the fridge. The 
solid was collected by filtration, washed with water and dried in oven (60 °C). The crude 
product was purified by flash column chromatography (SiO2, petroleum ether : EtOAc (9:1 
v/v)) to afford ICX1 (yield: 2.07%). 
 
 
Method B: GSS reaction (modified method for MW) 
A mixture of zinc chloride (13.25 g, 97.2 mmol) and phosphorus oxychloride (55 mL) 
was submitted to microwave irradiation at 400 W of potency during 10 min at 60 °C. Then, 
the 2,6-dihydroxybenzoic acid (5.00 g, 32.40 mmol) was added and the reaction mixture 
was subjected to microwave irradiation at 400 W of power for 10 min at 60 °C. Finally, 
phoroglucinol (4.10 g, 32.40 mmol) was added and the mixture was submitted to microwave 
irradiation at 400 W of power during 60 min at 60 °C. After cooling, the resulting mixture 
was quenched into crushed ice and extracted successively with CH2Cl2 (9 x 200 mL) and 
saturated aqueous NaHCO3 5% w/v (3 x 250 mL). The organic layers were dried over 
anhydrous Na2SO4 and evaporated under reduced pressure. The crude product was 
purified by flash column chromatography (SiO2, n-hexane : EtOAc (9.5:0.5 v/v)) to yield 
compound ICX1 as yellow solid (yield: 2.38%). 
 
m.p. 219-220 ºC; IR (KBr,  (cm-1)): 3500-3400 (OH); 1663 (C=O); 1601, 1565, 
1514, 1483 (aromatic C=C); 1293 (C-O); 1H NMR (300 MHz, DMSO-d6), δ (ppm): 11.89 (1 
H, s, OH-1), 11.81 (1 H, s, OH-8), 7.68 (1 H, brt, J = 8.4 Hz, H-6), 7.00 (1 H, dd, J = 8.4, 0.9 
Hz, H-5), 6.79 (1 H, dd, J = 8.4, 0.9 Hz, H-7), 6.38 (1 H, d, J = 2.1 Hz, H-4), 6.21 (1 H, d, J 
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= 2.1 Hz, H-2); 13C NMR (75.47 MHz, DMSO-d6), δ (ppm): 183.26 (C-9), 167.06 (C-3), 
162.16 (C-1), 160.27 (C-8), 157.51 (C-4a), 155.49 (C-10a), 137.18 (C-6), 110.60 (C-7), 
107.10 (C-5), 106.88 (C-8a), 101.00 (C-9a), 98.70 (C-2), 94.48 (C-4). 
 
 
3.2.2. Synthesis of 1,8-dihydroxy-3-methoxyxanthone (ICX2) 
 
 
A mixture of 1,3,8-trihydroxyxanthone (ICX1) (0.30 g, 1.23 mmol), methyl iodide 
(0.803 mL, 12.30 mmol, 10 equiv.) and anhydrous K2CO3 (0.21 g, 1.24 mmol,1 equiv.) in 
anhydrous acetone (40 mL) was stirred at reflux (60 ºC) for 3 h. The progress of the reaction 
was monitored by TLC. On completion, the solid was filtered, the solvent removed under 
reduced pressure and the crude product was purified by crystallization with acetone and by 
flash column chromatography (SiO2, n-hexane) to yield compound ICX2 as yellow needle 
solid. Yield: 74%; m.p. 170-172 ºC; IR (KBr,  (cm-1)): 3500-3400 (OH); 1662 (C=O); 1603, 
1568, 1505, 1470 (aromatic C=C); 2959, 2925, 2852 (aliphatic C-H); 1294 (C-O); 1H NMR 
(300 MHz, CDCl3), δ (ppm): 11.99 (1 H, s, OH-1), 11.92 (1 H, s, OH-8) , 7.56 (1 H, brt, J = 
8.4 Hz, H-6), 6.87 (1 H, dd, J = 8.4, 0.8 Hz, H-5), 6.78 (1 H, dd, J = 8.4, 0.8 Hz, H-7), 6.42 
(1 H, d, J = 2.3 Hz, H-4), 6.35 (1 H, d, J =2.3 Hz, H-2), 3.89 (3 H, s, 3- OCH3); 13C NMR 
(75.47 MHz, CDCl3), δ (ppm): 184.63 (C-9), 167.35 (C-3), 162.97 (C-1), 161.31 (C-8), 
157.78 (C-4a), 156.14 (C-10a), 136.80 (C-6), 110.89 (C-7), 106.96 (C-5), 106.96 (C-8a), 
102.70 (C-9a), 97.41 ( C-2), 93.10 (C-4), 55.93 (3- OCH3). 
 
 
3.2.3. Synthesis of 2- (dimethylamino)methyl)-1,8-dihydroxy-3-
methoxyxanthone (ICX2a) 
 
 
Dimethylamine (0.420 mL, 0.8395 mmol, 4.35 equiv.) was cooled in the ice bath for 
about 5 min and were added dropwise 37% formaldehyde solution (0.104 mL, 1.28 mmol, 
6.63 equiv.) and acetic acid (0.965 mL, 16.85 mmol). The reaction mixture was stirred at 
room temperature for 1 h and then, was added 1,8-dihydroxy-3-methoxyxanthone (ICX2) 
(0.050 g, 0.193 mmol). The mixture was stirred at room temperature for 6 days and then 
treated with water (5 mL) and continued stirring for about 12 h. The resulting solid was 
filtered and the filtrate was treated with NaOH (10% w/v) until the pH was 9~10. Finally, the 
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precipitate was also filtered, washed with water, dried and then purified by flash column 
chromatography (SiO2, petroleum ether:Chloroform:Ammonia (95:5:1 v/v/v)). Yield: 6.29%; 
m.p. 118-120 ºC; IR (KBr,  (cm-1)):  3600-3400 (OH); 1653 (C=O); 1605, 1558, 1539, 1490 
(aromatic C=C); 2923, 2853 (aliphatic C-H); 1296 (C-O); 1230 (C-N); 1H NMR (300 MHz, 
CDCl3), δ (ppm): 12.09 (1 H, s, OH-1), 12.09 (1 H, s, OH-8) , 7.55 (1 H, brt, J = 8.3 Hz, H-
6), 6.86 (1 H, brd, J = 8.3 Hz, H-5), 6.78 (1 H, brd, J = 8.3, Hz, H-7), 6.44 (1 H, s, H-4), 3.94 
(3 H, s, 3- OCH3), 3.64 (2 H, s, CH2N), 2.37 (6 H, s, N(CH3)2); 13C NMR (75.47 MHz, CDCl3), 
δ (ppm): 184.33 (C-9), 165.79 (C-3), 161.39 (C-1), 161.39 (C-8), 157.69 (C-4a), 155.96 (C-
10a), 136.58 (C-6), 110.90 (C-7), 107.85 (C-5), 106.79 (C-8a), 102.70 (C-9a), 103.5 (C-2), 
90.05 (C-4), 56.34 (3- OCH3), 49.97(CH2N), 44.96  (N(CH3)2). 
 
 
3.2.4. Synthesis of baicalein amino derivative (ICB1) 
 
 
Baicalein (B) (0.2 g, 0.74 mmol) was dissolved in methanol (100 mL) and to this 
solution were added dropwise 37% (v/v) formaldehyde solution (0.018 mL, 0.98 mmol, 1.32 
equiv.) and dimethylamine solution (1.00 mL, 2.00 mmol, 2.70 equiv.). The mixture was 
stirred at room temperature for 1 h 30 min. The precipitate was collected, filtered, and 
washed several times with methanol. Then, the precipitate was purified by flash column 
chromatography (SiO2, Chloroform:Methanol:Ammonia (90:10:2 v/v/v)). Yield: 10.50%; 
m.p. 286-288 ºC; IR (KBr,  (cm-1)): 3500-3250 (OH); 1667 (C=O); 1608, 1572, 1536, 1468 
(aromatic C=C); 2955, 2919 (aliphatic C-H); 1287 (C-O); 1247 (C-N); 1H NMR (300 MHz, 
CDCl3), δ (ppm): 12.52 (1 H, s, OH-5), 7.84- 7.82 (2 H, m, Ar-2’,6’-H), 7.54-7.52 (3 H, m, 
Ar-3’,4’,5’-H), 6.63 (1 H, s, H-3), 4.01 (2 H, s, CH2N), 2.45 (6 H, s, N(CH3)2);13C NMR (75.47 
MHz, CDCl3), δ (ppm): 182.53 (C-4), 162.60 (C-2), 153.65 (C-7), 147.17 (C-8a), 145.43 (C-
5), 132.05 (C-4’), 131.43 (C-1’), 129.10 (C-3’,5’), 126.02 (C-2’,6’), 119.78 (C-6), 105.18 (C-
4a), 104.31 (C-3), 98.54 (C-8), 55.39 (CH2N), 44.47 (N(CH3)2). 
 
 
3.3. Evaluation of the purity  
 
 
The purity of each compound was determined by HPLC-DAD. LC analysis was 
performed by isocratic elution using a mixture of MeOH:H2O:MeCO2H (70:30:1 v/v/v) as 
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mobile phase and the flow rate was set at 1 mL/min. The injected volume was 10 µL and 
the elution was monitored at 275 nm. The detector was set at a wavelength range of 220–
500 nm with a spectral resolution of 1 nm. The purity parameters included a 95% active 
peak region and a scan threshold of 5 mAU. 
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4. Conclusions 
 
 
The results obtained in different syntheses for xanthone and flavone derivatives 
allow us to draw some conclusions: 
 
- We could synthesize totally the building block ICX1 by two different one-spot 
methodologies: Eaton’s reaction and modified GSS reaction assisted by MW. These 
two strategies were not very effective for the synthesis of ICX1, because, although 
they had short reaction times, ICX1 was obtained with low yields; 
- The synthesis of ICX1 amino derivatives by Mannich reaction failed to obtain any 
Mannich base derivative; 
- In the methylation reaction of ICX1, its methylated derivative ICX2 was obtained in 
high yield (74%); 
- The amino derivative of ICX2 (ICX2a) was obtained by Mannich reaction with a low 
yield (6. 29%); 
- The Mannich reaction applied for baicalein (B) allowed to afford ICB1 with a 
relatively low yield (10.50%). 
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1. Antioxidant activity 
 
 
1.1. Introduction 
 
 
Nowadays, there are a wide variety of methods for evaluation of antioxidant activity 
of natural and synthetic compounds. The most commonly used assays to determine 
antioxidant activity can be divided in several categories according to the aims, namely 
assays to determine the ability of compounds to scavenge free radicals (specific ROS/RNS 
or stable, non-biological radicals), the reducing capacity, metal chelating activity, 
interference with antioxidant enzyme activity and inhibition of oxidative enzymes. These 
methods have been exhaustively reviewed by several authors 150-153.  
Among all these methods, the DPPH assay is clearly the most often used to assess 
the antioxidant capacity of xanthones and flavones 101,106,116,118,154-163. This choice is mainly 
due to the stability of this non-biological radical, which cannot dimerize unlike what happens 
with other free radicals. Moreover, it is a quick, easy and economical method and allows 
the analysis of multiple samples if is performed in microplates 164. 
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1.2. Results and discussion 
 
 
The antioxidant activity of all synthesized compounds has been evaluated. Besides 
this, this biological activity was also studied for other structure related aminoxanthonic 
derivatives previously synthesized in our research group (Figure 54).  
 
   
 
 
 
 
 
 
Figure 54. Basic structure of the aminoxanthonic derivatives previously synthesized in our research 
group. 
 
 
1.2.1. DPPH radical scavenging activity 
 
 
The DPPH assay is widely used to assess the ability of compounds to transfer labile 
H-atoms to this free radical. When this occurs, the color of DPPH radical changes from 
purple to yellow (non-radical form), being accompanied by a decrease in absorbance at 520 
nm 165. This assay was performed for all xanthonic and flavonic derivatives and the obtained 
results are summarized in Table 16.  
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Table 16. DPPH radical scavenging activity of tested compounds. 
Results are given as mean ± SEM of three independent experiments performed in triplicate; n.a..: not active; n.d.: not 
determined. Ascorbic Acid (positive control): IC50: 20.40± 0.000213 µM ***. *p<0.05; **p<0.01; ***p<0.001. 
 
 
Regarding xanthone derivatives, the results indicate that ICX1 and its methylated 
(ICX2) and Mannich base (ICX2a) derivatives did not possess scavenging activity against 
DPPH radical at 100 µM. At this concentration, the other aminoxanthones (except PPX4) 
showed activity against DPPH radical. Particularly, xanthones PPX1, PPX2 and PPX3 
demonstrated low activity, while PEX1 and PEX3 showed considerable scavenging activity 
at 100 µM, revealing IC50 values of 61.62 µM and 108.99 µM, respectively. 
For the tested flavones, these results show that baicalein (B) and its Mannich base 
derivative (ICB1) exhibited high free radical scavenging activity on DPPH assay, with IC50 
values of 35.09 ± 4.13 µM and 30.40 ± 1.28 µM, respectively. This DPPH scavenging 
activity was very similar for both flavonic compounds, showing that the presence of a 8-
(dimethylamino)methyl group on the flavone skeleton did not significantly alter its ability to 
scavenge free radicals. 
 
 
 
 
 
 
Compound % of scavenging DPPH 
radical at 100 µM 
IC50 (µM) 
ICX1 n.a. n.d. 
ICX2 n.a. n.d. 
ICX2a n.a. n.d. 
PPX1 5.92 ± 0.84** n.d. 
PPX2 2.32 ± 0.25* n.d. 
PPX3 5.74 ± 0.83* n.d. 
PPX4 n.a. n.d. 
PEX1 69.26 ± 2.11*** 61.62 ± 0.72*** 
PEX3 47.09 ± 1.35*** 108.99 ± 0.87*** 
B 96.03 ± 0.42*** 35.09 ± 4.13*** 
ICB1 93.93 ± 0.20*** 30.40 ± 1.28*** 
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1.2.2. Iron chelating activity 
 
 
We also explored the iron-chelating ability of all xanthones and flavones. In the 
method used, ferrozine forms complexes with Fe2+ and in the presence of chelating 
compounds, occurs a reduction in the formation of this complex, resulting in a decrease in 
the red color of this complex. Therefore, this chelating effect is due to the antioxidant 
capacity of tested compounds 73.  
The iron chelating activity of all tested compounds is summarized in Table 17. 
 
 
Table 17. Iron chelating activity of tested compounds. 
Compound % of chelation at 100 µM IC50 (µM) 
ICX1 12.19±2.55* n.d. 
ICX2 n.a. n.d. 
ICX2a 88.40 ± 0.56*** 65.94 ± 1.57*** 
PPX1 n.a. n.d. 
PPX2 n.a. n.d. 
PPX3 n.a. n.d. 
PPX4 n.a. n.d. 
PEX1 n.a. n.d. 
PEX3 n.a. n.d. 
B 18.24 ± 3.46* n.d. 
ICB1 49.90 ± 0.23*** 100 ± 0.21*** 
Results are given as mean ± SEM of three independent experiments performed in triplicate; n.a..: not active; n.d.: not 
determined. EDTA (positive control): IC50: 30.66 ± 0.17 µM ***. *p<0.05; ***p<0.001. 
 
 
The overall results indicate that among the tested xanthones, only ICX1 and ICX2a 
had chelating activity at 100 µM, being xanthone ICX2a the most active, with an IC50 value 
of 65.94 ± 1.57 µM.  
Comparing the iron chelating effects of the structure related xanthones ICX1, ICX2 
and ICX2a, it was found that not only the presence of an hydroxyl group instead of a 
methoxyl group at C-3 can favor the chelating activity, but also the presence of a 2-
(dimethylamino)methyl group on the xanthonic scaffold has an important role for this 
activity.  
For the tested flavones B and ICB1, both showed interesting chelating activity at 
100 µM, suggesting that the catechol moiety in the structure of these flavones was 
associated with their iron chelating capacity. In fact, it was reported that the presence of 
ortho-OH groups offers appropriate geometric and electronic environments to bind metal 
ions 38,39.  
  Chapter IV. Biological Activity 
85 
 
In the case of baicalein (B) and attending to its structure, it was expected an higher 
activity than that obtained in this assay because in several papers baicalein (B) showed a 
strong metal chelating activity 110,166-168. The same papers also reported that this strong 
chelating ability was linked to the presence of three adjacent hydroxyl groups and, 
consequently, the iron chelation will occur in the three different positions, such as, between 
C-4 oxo and C-5 hydroxyl group and between both hydroxyl groups at C-5 and C-6 or C-6 
and C-7 110,112,121,166-169. Additionally, Woźniak et al. reffered that in baicalein (B), chelation 
of iron can also take place between two molecules in C-6 and C-7 of the A ring, forming 
baicalein2-Fe2+ complexes, causing this configuration a stronger iron chelation 121.  
Moreover, comparing the chelating activity of B (18.24 ± 3.46%) with ICB1 (49.90 ± 
0.23%), it is possible to infer that the introduction of a 8-(dimethylamino)methyl group on 
the baicalein scaffold (B), forming its Mannich base analogue ICB1, was associated with 
an improvement of the iron chelating activity. 
 
 
1.2.3. Copper chelating activity 
 
 
The copper chelating activity of xanthones and flavones was assessed by UV-Vis 
spectroscopy, mainly through the detection of bathochromic shifts in the spectra of the 
tested compounds in the presence of Cu2+ ions at pH 7.4. For this, the UV-Vis spectra of 
each tested compound in PBS at pH 7.4 alone (red spectra, Figure 55; Figure 56 and 
Figure 57) and in the presence of a solution of CuSO4 50 µM (blue spectra, Figure 55; 
Figure 56 and Figure 57) or 25 µM (green spectra, Figure 55; Figure 56 and Figure 57) 
were recorded. In addition, the UV-Vis spectrum of each compound in the presence of 
CuSO4 25 µM after addition of EDTA 125 µM (pink spectra, Figure 55; Figure 56 and 
Figure 57) was also registered. 
 The results obtained for copper chelating activity of xanthone ICX1 and its 
derivatives ICX2 and ICX2a are showed in Figure 55; Figure 56 and Figure 57.  
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Figure 55. Copper interaction with ICX1 and its effect in UV-Vis spectrum of this compound. Red -
spectrum, ICX1 (25 µM); Blue - spectrum, ICX1 (25 µM) plus Cu2+ ions (50 µM); Green - spectrum, 
ICX1 (25 µM) plus Cu2+ ions (25 µM); Pink - spectrum, ICX1 (25 µM) plus Cu2+ ions (25 µM) after 
addition of EDTA (125 µM). 
Figure 56. Copper interaction with ICX2 and its effect in UV-Vis spectrum of this compound. Red -
spectrum, ICX2 (25 µM); Blue - spectrum, ICX2 (25 µM) plus Cu2+ ions (50 µM); Green - spectrum, 
ICX2 (25 µM) plus Cu2+ ions (25 µM); Pink - spectrum, ICX2 (25 µM) plus Cu2+ ions (25 µM) after 
addition of EDTA (125 µM). 
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The differences observed in the spectrum of ICX1 after the addition of Cu2+ (blue 
and green spectra, Figure 55) in comparison with the spectrum in the absence of this metal 
ion (red spectrum, Figure 55) and the regeneration of the original spectrum (pink spectrum, 
Figure 55) after the addition of EDTA suggest that ICX1 has some Cu2+ chelating effect. 
Nevertheless, no chelating activity was observed for the ICX1 methylated derivative 
(ICX2) since all spectra are overlapped (Figure 56).  
For ICX2 Mannich base derivative (ICX2a) some chelating activity was observed. In 
fact, interactions of ICX2a with Cu2+ ions at 25 µM (green spectrum, Figure 57) and 50 µM 
(blue spectrum, Figure 57) produced bathochromic shifts in band at 250 nm of 18 nm (Table 
18) and 24 nm (Table 18), respectively, associated with a small decrease in absorbance. 
Although no changes in the position of the band at 324 nm were detected, it was observed 
an increase in absorbance for wavelengths near 400 nm (absorbance increased from 0.05 
to 0.118) in the spectrum of ICX2a plus Cu2+ (blue and green spectra, Figure 57).  
 
 
 
Figure 57. Copper interaction with ICX2a and its effect in UV-Vis spectrum of this compound. Red-
spectrum, ICX2a (25 µM); Blue - spectrum, ICX2a (25 µM) plus Cu2+ ions (50 µM); Green - spectrum, 
ICX2a (25 µM) plus Cu2+ ions (25 µM); Pink - spectrum, ICX2a (25 µM) plus Cu2+ ions (25 µM) after 
addition of EDTA (125 µM). 
ICX2a 
 ICX2a (25 µM) 
 ICX2a (25 µM) + CuSO4 50 µM 
 ICX2a (25 µM) + CuSO4 25 µM 
 ICX2a (25 µM) + CuSO4 25 µM + EDTA 125 
µM 
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Table 18. UV spectral shifts of ICX2a. 
 max (nm) 
Xanthone Spectra in 
PBS pH 7.4 
Spectra in PBS pH 
7.4 with CuSO4 50 
µM 
Spectra in PBS pH 
7.4 with CuSO4 25 
µM 
Spectra in PBS pH 7.4 
with CuSO4 25 µM and 
EDTA 125 µM 
ICX2a 250 274 268 250 
 
 
In conclusion, comparing the results obtained for ICX2 and ICX2a, is possible to 
infer that the aminomethylation at C-2 of the xanthone nucleus potentiates its chelating 
activity.  
Considering the spectra obtained for aminoxanthones PPX1, PPX2, PPX3, PPX4, 
PEX1 and PEX3 presented in Figure 58, no chelating activity was detected since the 
spectrum of each compound in the presence of copper was overlapped with the spectrum 
of the compound alone. 
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Figure 58. Copper interaction with PPX1, PPX2, PPX3, PPX4, PEX1 and PEX3 and its effect in UV-
Vis spectrum of each compound. Red - spectrum, PPX1, PPX2, PPX3, PPX4, PEX1 and PEX3 (25 
µM); Blue - spectrum, PPX1, PPX2, PPX3, PPX4, PEX1 and PEX3 (25 µM) plus Cu2+ ions (50 µM); 
Green - spectrum, PPX1, PPX2, PPX3, PPX4, PEX1 and PEX3 (25 µM) plus Cu2+ ions (25 µM); Pink 
- spectrum, PPX1, PPX2, PPX3, PPX4, PEX1 and PEX3 (25 µM) plus Cu2+ ions (25 µM) after 
addition of EDTA (125 µM). 
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The results obtained for copper chelating activity of the tested flavones B and ICB1 
are illustrated in Figure 59. 
The interactions of baicalein (B) with Cu2+ produced hypsochromic shifts (10 nm) in 
band at 266 nm (blue and green spectra, Figure 59) and slight bathochromic shifts in band 
at 359 nm of 6 nm (with CuSO4 50 µM, blue spectrum, Figure 59) and 3 nm (with CuSO4 
25 µM, green spectrum, Figure 59). Moreover, the addition of EDTA (pink spectrum, Figure 
59) regenerated the original spectrum (Table 19). 
The interaction of copper with baicalein Mannich base derivative (ICB1) also 
induced changes in its spectrum. Particularly, this interaction caused bathochromic shifts in 
band at 268 nm of 18 nm for both copper concentrations (50 µM and 25 µM, blue and green 
spectra, Figure 59). In addition, a slight hypsochromic shift (6 nm) accompanied by a 
decrease in absorbance for compound plus Cu2+ at 50 µM and 25 µM was observed for the 
band at 362 nm (blue and green spectra, Figure 59). On addition of EDTA, the original 
spectrum was recovered (pink spectrum, Figure 59). Thus, according to these results, it 
can be concluded that ICB1 as wells as the precursor (B) possess copper chelating activity. 
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Table 19. UV spectral shifts of B and ICB1. 
 
 
Flavone 
max (nm) 
Spectra in PBS pH 
7.4 
Spectra in PBS pH 
7.4 with CuSO4 50 
µM 
Spectra in PBS pH 
7.4 with CuSO4 25 
µM 
Spectra in PBS pH 
7.4 with CuSO4 25 
µM and EDTA 125 
µM 
B 
 
266 256 256 266 
359 365 362 359 
ICB1 268 284 284 268 
362 356 356 362 
A1-Spectrum
A9-Spectrum
A3-Spectrum
A4-Spectrum
Wavelength (nm)
O
D
200 300 400 500 600 700 800
0,000
0,050
0,100
0,150
0,200
0,250
0,300
0,350
0,400
0,450B 
 B (25 µM) 
 B (25 µM) + CuSO4 50 µM 
 B (25 µM) + CuSO4 25 µM 
 B (25 µM) + CuSO4 25 µM + EDTA 125 µM 
B1-Spectrum
B2-Spectrum
B3-Spectrum
B4-Spectrum
Wavelength (nm)
O
D
200 300 400 500 600 700 800
0,000
0,100
0,200
0,300
0,400
0,500
0,600
ICB1 
 ICB1 (25 µM) 
 ICB1 (25 µM) + CuSO4 50 µM 
 ICB1 (25 µM) + CuSO4 25 µM 
 ICB1 (25 µM) + CuSO4 25 µM + EDTA 125 µM 
Figure 59. Copper interaction with B and ICB1 and its effect in UV-Vis spectrum of each compound. 
Red - spectrum, B and ICB1 (25 µM); Blue - spectrum, B and ICB1 (25 µM) plus Cu2+ ions (50 µM); 
Green - spectrum, B and ICB1 (25 µM) plus Cu2+ ions (25 µM); Pink - spectrum, B and ICB1 (25 µM) 
plus Cu2+ ions (25 µM) after addition of EDTA (125 µM). 
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2. Acetylcholinesterase inhibitory activity 
 
 
2.1. Introduction 
 
 
In recent years, various methods for screening of AChE inhibitory activity have been 
described 170. 
In 1961, Ellman et al. have described a photometric method for the determination of 
anticholinesterase activity. This assay is based on measuring the rate of production of 
thiocholine, as ACh is hydrolyzed by AChE. This is possible because the thiol group of the 
thiocholine reacts with Ellman's reagent to produce a yellow anion of 5-thio-2-nitrobenzoic 
acid (Figure 60). In turn, the presence of this anion can be detected by reading the 
absorbance at 412 nm. However, this method requires that all reagents and samples have 
a high water solubility 171.  
 
 
 
 
 
 
 
Figure 60. Sequence of reactions for detection of AChE activity by the Ellman’s method (adapted 
171). 
 
 
In order to overcome this problem, Rhee et al. (2001) have developed a rapid and 
efficient assay for the detection of AChE inhibitors that are in complex matrices. This method 
which was based on the methodology previously described by Kiely et al. (1991), uses the 
TLC and Ellman's reagent 172,173. Thus, in this assay, the presence of compounds with 
anticholinesterase activity is detected by the appearance of white stains over the yellow 
background in the chromatographic plate. This method is widely used because it allows 
rapid and direct analysis of the inhibitory activity of compounds in extracts or fractions, 
without prior isolation. However, in this method, false-positive results can be obtained. 
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These false-positive results are due to the fact that some compounds (aldehydes and 
amines) may interact in the second step of the reaction preventing the formation of the 
yellow compound 173. 
In 2001, this research group has also adapted for the microscale the methodology 
developed by Ellman et al., by  simply monitoring the production of colored compound in 
96-well plates using a microplate reader. This assay revealed to be more sensitive than the 
TLC method; allowed greater automation and a faster analysis of a larger number of 
samples 173. 
Marston et al., in 2002, developed another method based on TLC. This assay utilizes 
a different reaction, where the substrate α-naphthyl acetate is hydrolyzed by 
acetylcholinesterase, forming α -naphthol. This reacts with the colorimetric reagent Fast 
Blue Salt B to produce a diazonium salt (violet) (Figure 61). Thus, the AChE inhibitors are 
directly detected by the presence of white stains over the violet background in the 
chromatographic plate. It should be noted that this test does not require the false-positive 
tests 174. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 61. Reaction from detection of AChE activity by the Marston’s method (adapted 174). 
 
 
In addition to this methodology based on TLC, other assays for the screening of 
AChE inhibitors have been developed using HPLC. Andrisano et al., in 2001, have created 
a method for determining the anticholinesterase activity by HPLC, using an AChE 
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derivatized column, connected with a DAD detection system. This methodology also makes 
use of the substrate acetylthiocholine and it is based on the conventional measurement (by 
ultra-violet) of the production of yellow compound in the presence of potential 
anticholinesterase agent. Thus, due to the automation of the HPLC system, this method 
allows the continuous analysis of several compounds 175. 
Over the years, other methods were also developed for the assessment of 
anticholinesterase activity, such as fluorometric methods with fluorogenic substrates; 
radiometric assays; methods based on electrochemical activity or pH change 170,176,177. 
In 2003, a fluorometric flow method has been developed by Rhee et al. to determine 
the anticholinesterase activity in plant extracts. These researchers created this assay in 
order to improve the sensitivity of the HPLC coupled colorimetric flow assay that had already 
been developed. This fluorometric method is based on the use of the direct fluorogenic 
substrate 7-acetoxy-1-methylquinolinium iodide (AMQI), a fluorescent compound with 
excitation = 320 nm and emission  = 410 nm. In this case, the substrate AMQI is hydrolyzed by 
AChE forming the 7-hydroxy-1-methylquinolinium iodide (HMQI), an highly fluorescent 
compound with excitation = 406 nm and, emission = 505 nm (Figure 62). Then, the production 
of the HMQI is detected using a fluorometer. The use of a direct fluorogenic substrate 
reduces the risk of false - positive results 177. 
 
 
 
 
 
 
 
Figure 62. Conversion of 7-acetoxy-1-methylquinolinium iodide to 7-hydroxy-1-methylquinolinium 
iodide by AChE (adapted 177). 
 
 
Despite all of these methods that have been developed, the evaluation of the 
anticholinesterase activity of xanthone and flavone derivatives is performed mainly using 
the two methods described by Ellman in 1961 and Rhee in 2001 41,42,56,62,107,178. These two 
methods are widely used to test the anticholinesterase activity of xanthones and flavones, 
because they are easy to perform and allow getting information very quickly. In addition, 
these assays do not require very expensive equipment and allow analyzing various natural 
crude extracts at the same time 170. 
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Particularly, Ellman’s assay is more used than Marston’s method because the 
substrate acetylcholine and the Ellman’s reagent are more stable and soluble in the buffer 
than -naphthyl acetate. Thus, the first assay avoids the use of large amounts of DMSO as 
solvent. This aspect is very important, because it was observed in screening tests that 
DMSO also showed ability to inhibit the AChE, affecting the kinetics of inhibition of the tested 
compounds. Also, the method developed by Ellman requires a lower amount of enzyme 
and the formation of product of enzymatic reaction can be monitored continuously 170. 
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2.2. Results and discussion 
 
 
The AChE inhibitory activity of all synthesized compounds as well as of other 
structure related aminoxanthonic derivatives previously synthesized in our research group 
has been evaluated (see section 1.2.). For screening of AChE inhibitory activity of all 
xanthone and flavones, we applied the photometric assay described by Ellman et al. with 
some modifications 171. In this assay, the thiol group of the thiocholine reacts with Ellman's 
reagent to produce a yellow anion of 5-thio-2-nitrobenzoic acid. In the presence of an AChE 
inhibitor, the rate of production of thiocholine decreases and consequently, decreases the 
production of this cation that can be detected by reading the absorbance at 412 nm. 
The results obtained for the AChE inhibitory activity of all tested compounds are 
summarized in Table 20. 
 
 
Table 20. AChE inhibitory activity of tested compounds. 
Compound % of inhibition at 100 µM IC50 (µM) 
ICX1 n.a. n.d. 
ICX2 34.04 ± 3.12* n.d. 
ICX2a 49.08 ± 2.78** 100.00 ± 2.76** 
PPX1 29.28 ± 5.79** n.d. 
PPX2 17.34 ± 2.45* n.d. 
PPX3 21.50 ± 4.023* n.d. 
PPX4 29.74 ± 3.70** n.d. 
PEX1 n.a. n.d. 
PEX3 n.a. n.d. 
B n.a. n.d. 
ICB1 69.34 ± 0.72** 81.99 ± 1.16** 
Results are given as mean ± SEM of three independent experiments performed in triplicate; n.a..: not active; n.d.: not 
determined. Galantamine (positive control): IC50: 6.59 ± 0.15 µM ***. *p<0.05; **p<0.01; ***p<0.001. 
 
 
The overall results indicate that most of the xanthones evaluated exhibited AChE 
inhibitory activity, except xanthones ICX1, PEX1 and PEX3.  
Additionally, our results show that the methylation of ICX1, led to the formation of a 
methyl derivative ICX2 with inhibitory activity at 100 µM (% of AChE inhibition = 34.04 ± 
3.12). Therefore, this suggests that the introduction of a methyl group at C-3 of the ICX1 
skeleton enhances its AChE inhibitory activity. 
 Comparing the results obtained for ICX1, ICX2 and ICX2a, it was found that the 
Mannich base analogue ICX2a was the most active xanthone with an IC50 value of 100.00 
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± 2.76 µM. Thus, the presence of a 2-(dimethylamino)methyl group on the xanthone nucleus 
appears to be an important role for AChE inhibition. 
Regarding the tested flavones, in opposition to baicalein (B) which did not possess 
AChE inhibitory activity, its Mannich base derivative ICB1 reveals to be a moderate AChE 
inhibitor, showing an IC50 value of 81.99 ± 1.16 µM. Considering this, it can be concluded 
that the presence of a 8-(dimethylamino)methyl group on the flavone skeleton is responsible 
for its AChE inhibitory activity. 
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3. Xanthones and flavones as dual agents: antioxidants and AChE 
inhibitors 
 
 
AD is the most prevalent form of dementia and it is known that the malfunctions of 
different, but interconnected, biochemical complex pathways are related to this 
pathogenesis. Inhibition of AChE is one of the most accepted therapy strategies for AD, like 
already described in this thesis. Consequently, several AChE inhibitors have been approved 
for commercial use. Nevertheless, these AChE inhibitors show lack selectivity for AChE and 
AD-patients suffer from side-effects. Therefore, there is a considerable need for strategies 
for development of new AChE inhibitors 4. Due to the multifactorial nature of AD, this 
disease requires new therapeutic strategies. Among the multipotent approaches, the 
association between cholinesterase inhibition and antioxidant activity has been considered 
as an attractive methodology 38,39.  
Considering that concept, the main aim of this work consists in obtaining new AChE 
inhibitors with antioxidant activity based on the xanthonic and flavonic scaffolds.  
Taking into account the results obtained for antioxidant activity (DPPH radical 
scavenging activity and iron and copper chelating activities) and the AChE inhibitory 
property for all xanthones and flavones tested in this work (sections 1.2. and 2.2.), it can be 
seen that only Mannich base analogues of xanthone (ICX2a) and flavone (ICB1) showed 
both activities.  
Attending to these results (Table 21), it can be verified that ICX2a and ICB1 had 
moderate AChE inhibitory activities, being ICB1 the most active compound. However, their 
antioxidant properties are slightly different. While ICX2a exerted its antioxidant activity by 
chelating metal ions, ICB1 was an antioxidant agent through scavenging free radicals, as 
well as by chelation metal ions.  
 
 
Table 21. DPPH radical scavenging, iron chelating and AChE inhibitory activities of ICX2a and 
ICB1.  
Compound DPPH, IC50 (µM) Iron chelation, 
IC50 (µM) 
Copper 
chelation 
AChE inhibition, 
IC50 (µM) 
ICX2a n.a. 65.94 ± 1.57*** bathochromic 
shifts on the 
spectrum 
100.00 ± 2.76** 
ICB1 30.40 ± 1.28*** 100.00 ± 0.23*** bathochromic 
shifts on the 
spectrum 
81.99 ± 1.16** 
Results are given in mean ± SEM of three independent experiments performed in triplicate; n.a..: not active; **p<0.01; ***p<0.001. 
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Therefore, from this study, the Mannich base derivatives ICB1 and ICX2a emerged 
as dual agents with antioxidant and AChE inhibitory activities. Thus, it can be concluded 
that these compounds constitute promising multipotent agents for treating AD and possibly, 
they can be hit compounds for the design and synthesis of other xanthonic and flavonic 
compounds with these desired biological/pharmacological activities.  
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4. Experimental  
 
 
4.1. DPPH radical scavenging activity 
 
 
Scavenging activities of the all xanthone and flavone derivatives for stable 1,1- 
diphenyl-2-picrylhydrazyl (DPPH) free radical were evaluated according to a method 
previously described 179,180 with some modifications. A solution of the radical DPPH in 
methanol was prepared daily and protected from light. Reaction mixtures containing 100-
1.56 µM of the tested compounds solutions in methanol (100 µL) and 0.03 mg/mL DPPH 
methanolic solution (100 µL) in a 96 well microtiter plates were shaken and incubated for 
30 min in darkness at room temperature (until stable absorbance values were obtained). 
Controls containing 100 µL of methanol instead of compounds and 100 µL of DPPH 
methanolic solution (0.03 mg/mL) and blanks containing 200 µL of methanol were also 
made. In this assay, sample’s blanks containing 100 µL of methanol instead of DPPH 
methanolic solution were also performed. 
The absorbances were measured at 520 nm in a microplate reader (BioTeck 
Instruments, Vermont, US). The percentage of inhibition activity was calculated as:  
 
DPPH radical scavenging effect (%) = [1-(A1-Abs/A0-Ab)] × 100 
  
where A0 was the absorbance of control, Abs was the absorbance of sample’s blanks, 
Ab was the absorbance of blank and A1 was the absorbance in the presence of the positive 
control or tested compounds at different concentrations. Ascorbic acid was used as positive 
control as well as for validating of the method. All the tests were performed in triplicate. The 
scavenging activities of the tested compounds towards DPPH radical were expressed as 
IC50, which was determined to be the effective concentration at which DPPH radical was 
scavenged by 50%. The IC50 value was obtained by interpolation from linear regression 
analysis. 
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4.2. Iron chelating activity 
 
 
The chelation of iron ions by xanthone and flavone derivatives was assessed by the 
methodology described by Dinis et al. with modifications 181. This assay was performed in 
a 96 well plate and the absorbance was measured at 562 nm. Briefly, 10 µL of FeCl2 (50 
µM) were added to a 50 µL of solution of compounds in different concentrations (100-75 
µM) and 120 µL of methanol. The mixture was allowed to stand 5 minutes and the reaction 
was initiated by the addition of 20 µL of 3-(2-pyridyl)-5,6-bis(4-phenylsulphonic acid)-1,2,4-
triazine (ferrozine, 100 µM) and the mixture was shaken at room temperature for 10 min. 
Then, the absorbance of the solution was measured in a microplate reader (BioTeck 
Instruments, Vermont, US). Controls containing 50 µL of solvent instead of compounds and 
blanks containing 50 µL of solvent instead of compounds and 20 µL milliQ™ purified water 
instead of ferrozine were made. In this assay, sample’s blanks containing 20 µL milliQ™ 
purified water instead of ferrozine were also performed. 
All tests and analyses were carry out in triplicate and EDTA was used as positive 
control as well as for validating the method. The percentage of inhibition of Fe2+–ferrozine 
complex formation was given below:  
 
%Inhibition = [((C-C0)-(S-S0))/(C-C0)] × 100 
 
where C was the absorbance of the control, C0 was the absorbance of the blank, S 
was the absorbance in the presence of the solutions of compounds and S0 was the 
absorbance of sample’s blank. The chelating activities of the purified compounds towards 
iron ions were expressed as IC50, which was determined to be the effective concentration 
at which iron ions were chelated by 50%. The IC50 value was obtained by interpolation from 
linear regression analysis. 
 
 
4.3. Copper chelating activity 
 
 
The chelation of copper ions by xanthone and flavone derivatives was estimated in 
consistent with Brown et al. 182 and adapted to a 96 well plate. Stock solutions of each 
compound (1 mM) were prepared in methanol or DMSO, and then, 50 µM of these solutions 
were prepared with PBS solution (10 mM) pH 7.4 and 50 µL of each was taken to 96 well 
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UV plate (well A-D). Then, 100 µL of ultra pure water (well A), or 50 µL of ultra pure water 
and 50 µL CuSO4 (200 µM) (well B), or 50 µL of ultra pure water and 50 µL of CuSO4 (100 
µM) (well C), or 50 µL of EDTA (500 µM) and 50 µL CuSO4 (200 µM) (well D) was added. 
The absorption spectra were recorded between 200 and 800 nm in a micro plate reader 
(BioTeck Instruments, Vermont, US), and the scans in the presence of 1:1 (green spectrum) 
and 2:1 (blue spectrum) of copper-to-compound ratios were compared with the scan with 
compound alone (red spectrum). All tests and analyses were carried out in triplicate. 
 
 
4.4.  Acetylcholinesterase inhibitory activity 
 
 
Acetylcholinesterase inhibitory activity was measured using the Ellman’s microplate 
assay with modification 171. Briefly, for AChE inhibitory assay, 20 µL of 0.22 U/mL AChE 
from Electrophorus electricus was added to the wells containing 20 µL of tested compounds 
(100 µM in methanol or DMSO), 100 µL of 3 mM 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) 
and 20 µL of 15 mM acetylthiocholine iodide. Absorbance of the colored end product was 
measured at 412 nm for 10 minutes. Controls containing 20 µL of methanol instead of 
compounds and blanks containing 20 µL of buffer (0.1% (w/v) bovine serum albumin in 50 
mM Tris-HCl) instead of enzyme were made. In this assay, sample’s blanks containing 20 
µL of buffer (0.1% (w/v) bovine serum albumin in 50 mM Tris-HCl) instead of AChE were 
also performed. Percentage of enzymatic inhibition was calculated as: 
Percentage of inhibition = 100 - [((S-S0)/(C-C0)) x100] 
 
where C was the absorbance of the control, C0 was the absorbance of blank, S was 
the absorbance in the presence of the sample compounds and S0 was the absorbance of 
sample’s blank. Every experiments were done in triplicate and galantamine was used as 
positive control as well as for validating the method. The inhibitory activities of the purified 
compounds towards AChE were expressed as IC50, which was determined to be the 
effective concentration at which AChE was inhibited by 50%. The IC50 value was obtained 
by interpolation from linear regression analysis. 
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4.5. Statistical analyses 
 
 
Data were reported as means ± standard error of the mean (SEM) of at least three 
independent experiments. Statistical analysis of the results was performed with GraphPad 
Prism (GraphPad Software, San Diego, CA). Unpaired t-test were carried out to test for any 
significant differences between the means. Differences at the 5% confidence level were 
considered significant. 
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5. Conclusions 
 
 
Considering the results obtained in the biological evaluation of the antioxidant and 
AChE inhibitory activities of all xanthone and flavone derivatives some conclusions can be 
made: 
 
- On DPPH assay, baicalein (B) and its Mannich base analogue ICB1 were the most 
active compounds, with IC50 values of 35.09 µM and 30.40 µM, respectively; 
- Xanthones PEX1 and PEX3 were the most active xanthonic derivatives against 
DPPH free radical, with IC50 values of 61.62 µM and 108.99 µM, respectively; 
- In the iron chelation assay, Mannich base derivatives ICX2a and ICB1 had 
interesting chelating effect, showing IC50 values of 65.94 µM and 100.00 µM, 
respectively; 
- Xanthones ICX1 and ICX2a, as well as baicalein (B) and its Mannich derivative ICB1 
were the only compounds that showed copper chelating activity; 
- Xanthones ICX2, PPX1, PPX2, PPX3 and PPX4 showed some activity against 
AChE at 100 µM; 
- In AChE assay, Mannich base derivatives ICX2a and ICB1 had moderate activity, 
being ICB1 the most active compound (IC50 value of 81.99 µM); 
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1. Results and discussion 
 
 
In the current work, a flavone amino derivative ICB1 has been discovered with 
moderate activity against AChE. Since its inhibitory mechanism against AChE is still 
unclear, the binding mechanism was studied by molecular docking. In addition to ICB1, 
docking studies were also performed for a series of compounds already described in the 
literature as AChE inhibitors 183, being these used as positive controls. For these molecules 
docking scores values ranging from -5.7 to -12.1 kcal.mol-1 were obtained (Table 22). The 
ICB1:AChE complex originated a free binding energy within that range (-10 kcal.mol-1), 
suggesting the formation of a stable complex between ICB1 and AChE. 
 
 
Table 22. Docking scores of known AChE inhbitors and ICB1. 
Compound Docking scores (kcal.mol-1) 
Trichlorfon -5.7 
Echothiophate -5.9 
Isoflurophate -5.9 
Pyridostigmine -6.3 
Neostigmine -7.5 
Parathion -7.6 
Rivastigmine -7.9 
Tacrine -8.8 
Ladostigil -9.1 
Physostigmine -9.1 
HuperzineA -9.7 
Ungeremine -10 
Galantamine -10.2 
Donepezil -12.1 
ICB1 -10 
 
 
In order to further understand the binding mode of the ICB1 to AChE, a careful 
inspection of the most stable docking pose of that small molecule was performed. 
 AChE is a serine hydrolase and the crystallographic structures reveal the presence 
of a narrow, long, and hydrophobic cavity (Figure 63A). The active site of AChE comprises 
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2 subsites - the esteratic and anionic subsites 183. The esteratic subsite, where AChE is 
hydrolyzed to acetate and choline, contains the catalytic triad of three amino acids: Ser203, 
His447, and Glu334, the lining of which contains mostly aromatic residues that form a 
narrow entrance to the catalytic Ser203 184. The activation of Ser203 allows the acylation 
between hydroxyl group of that residue and AChE oxygen.  In the anionic site, the indole 
side chain of the conserved residue Trp86 makes a cation-π interaction with the quaternary 
amino group of AChE. A peripherical site is composed of several aromatic residues, lining 
an hydrophobic region that traps AChE and transfers it to the deep catalytic site 185.  
 
 
Figure 63. (A) AChE (surface) and docked ICB1 (blue sticks). (B) AChE active site (surface) bound 
to ICB1 (blue sticks). Residues involved in hydrogen interactions (yellow broken line) and π stacking 
interactions (yellow double arrow) are displayed using a stick model. AChE carbon, oxygen, nitrogen, 
and hydrogen are represented in green, red, blue, and grey, respectively. (C) 2D depiction of the 
ICB1 docked into the binding site of AChE highlighting the protein residues that form the main 
interactions with the different structural units of the inhibitor. Hydrogen-bonding interactions are 
represented with yellow broken lines. π stacking interactions are represented with a yellow double 
arrow. Receptor residues that are close to the ICB1, but whose interactions with the ligand are weak 
or diffuse, such as collective hydrophobic or electrostatic interactions, are also represented (all the 
ones that have no indication for hydrogen-bonding or π stacking). Hydrophobic residues are colored 
with a green interior, polar residues are colored in light purple, basic residues are annotated by a 
blue ring, and acidic residues with a red ring. Solvent accessible surface area of the ICB1 is plotted 
directly onto the atoms in the form of a blue smudge.  
 
The interactions between inhibitors such as donepezil, galantamine, huperzine A, 
and the enzyme, as observed from their crystallographic structures (Figure 64), are 
characterized by hydrogen bonds; and π-π stacking and cation-π interactions involving 
aromatic residues of AChE 186. Most ligands are located at the bottom of the binding groove 
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that form a hydrophobic pocket base, although larger ligands as donepezil extend to the 
periphery of the pocket. 
The narrower gorge in AChE results in a conformation where the phenyl ring of the 
ICB1 packs against the aromatic hydrophobic portions of the side chain of Phe-338. 
Packing in this region is quite tight, and only the smallest substituents might be 
accommodated. In contrast, the chromenone ring system of the flavone molecule faces a 
larger, negatively charged, and hydrophilic cavity, that includes hydroxyl and carbonyl 
groups of Gly120, Ser125, Tyr133, and Glu202. Upon analysis of the interaction of the ICB1 
in AChE binding site domains, it is observed that the residues Gly120, Ser125, Tyr133, and 
Glu202 participate in H-interactions. These residues are present in the buried region of the 
groove. π stacking interactions are established between the phenyl ring of the ICB1 and 
Phe338. Although the ICB1 has a protonable amine group, and cation-π interactions 
between protonated nitrogens and AChE aromatic residues is described as being important 
for the activity of the highly potent inhibitors, such as donepezil (Figure 64A and Figure 
64B), this interaction is not predicted to occur between ICB1 and AChE binding site (Figure 
63B and Figure 63C).   
Therefore, molecular modifications on the flavone scaffold placing the amine group 
on different positions on A ring will be further explored in order to facilitate a cation-π 
interaction. Moreover, molecular modifications that would allow the establishment of 
hydrogen interactions with the catalytic residue Ser203 (described for galantamine; Figure 
64C and Figure 64D); and elongation of the molecule that would favor the establishment of 
additional π-π or cation-π interactions with residues such as Trp86, Trp286, or Tyr337 
(described for donepezil and huperzine A; Figure 64A, Figure 64B, Figure 64E and Figure 
64F), are foreseen as being important for the AChE inhibitory ability of flavones. 
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Figure 64. AChE active site (surface) bound to crystallographic donepezil (pdb ID: 4EY7) (A), 
galantamine (pdb ID: 4EY6) (C), and huperzine A (pdb ID: 4EY5) (E) (blue sticks). Residues involved 
in hydrogen interactions (yellow broken line), π stacking interactions (yellow double arrow), and π-
cation interactions (orange double arrow) are displayed using a stick model. AChE carbon, oxygen, 
nitrogen, and hydrogen are represented in green, red, blue, and grey, respectively.  
2D depiction of crystallographic donepezil (B), galantamine (D), and huperzine A (F) in the binding 
site of AChE, highlighting the protein residues that form the main interactions with the different 
structural units of the inhibitor. Hydrogen-bonding, π stacking, and π-cation interactions are 
represented with yellow broken lines, yellow double arrow, and orange double arrow, respectively. 
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2. Experimental  
 
 
Crystal structure of AChE (PDB code: 4EY7) 186, downloaded from the protein 
databank (PDB) (2) 187, was used for the study. Structure files of 14 known AChE inhibitors 
and ICB1 were created and minimized using the chemical structure drawing tool 
Hyperchem 7.5 (Hypercube, FL, USA) 188. Structure-based docking was carried out using 
AutoDock Vina (Molecular Graphics Lab, CA, USA) 189. The active site was defined as the 
region of AChE that comes within 12 Å from the crystallographic ligand. Default settings for 
small molecule-protein docking were used throughout the simulations. Top 9 poses were 
collected for each molecule and the lowest docking score value was associated with the 
more favorable binding conformation. PyMol1.3 (Schrödinger, NY, USA) 190 and MOE 
(Chemical Computing Group, Montreal, Canada) 191 was used for visual inspection of results 
and graphical representations. 
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3. Conclusions 
 
 
Considering the results obtained in the docking studies of ICB1 with AChE, some 
conclusions can be draw: 
 
- Docking studies indicated that ICB1 binds stably to enzyme with a free binding 
energy of – 10 kcal.mol-1; 
- Docking analyzes also showed that hydroxyl and carbonyl groups of ICB1 establish 
hydrogen interactions with the Gly120, Ser125, Tyr133, and Glu202 residues of 
AChE which are situated in the buried region of the groove. Additionally, the phenyl 
ring of ICB1 establishes π stacking interactions with Phe338 residue of AChE. 
Cation-π interactions between protonated nitrogens of ICB1 and AChE aromatic 
residues were not observed. 
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Considering the proposed objectives indicated previously, the following main 
conclusions from this work are as follow: 
 
- Hydroxylated xanthone ICX1 was obtained by two synthetic strategies: Eaton’s 
reaction and GSS; 
- The synthetic approach used for obtaining methylated derivative of ICX1 was 
successfully applied, affording ICX2 in high yield and with moderate reaction time; 
- Amino derivatives of ICX2 and B were obtained (ICX2a and ICB1, respectively) by 
applying the Mannich reaction. However, this synthetic approach was not suitable 
to the synthesis of the amino derivative of ICX1, because in this reaction several by-
products were generated; 
- Xanthone ICX1 showed some antioxidant activity by chelation iron and copper ions, 
but did not possess AChE inhibitory activity; 
- Xanthones PEX1 and PEX3 only had moderate antioxidant activity by scavenging 
DPPH free radical; 
- Xanthone ICX2a showed antioxidant activity by chelation iron and copper ions.  
- Flavones B and ICB1 exerted their antioxidant activity through DPPH scavenging 
free radical and by chelation metal ions; 
- ICX2a was the most active xanthone against AChE; 
- Among all tested compounds, Mannich base derivative of baicalein ICB1 was the 
most active compound with AChE inhibitory activity;  
- ICX2a and ICB1 were the only compounds that showed dual activity (antioxidant 
and AChE inhibitory activities); 
- Docking studies of the most active compound ICB1 with AChE showed that this 
Mannich base derivative binds stably to enzyme; 
- The principal interactions established between ICB1 and AChE are: hydrogen 
interactions between the hydroxyl and carbonyl groups of ICB1 and Gly120, Ser125, 
Tyr133, and Glu202 residues of AChE that are present in the buried region of the 
groove and π stacking interactions between the phenyl ring of ICB1 and Phe338 
residue of AChE. 
 
This work allowed the identification of xanthone and flavone Mannich base 
derivatives with dual activity that may will serve as model for the design and synthesis of 
new xanthonic and flavonic derivatives with potential AChE inhibitory and antioxidant dual 
activity.  
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In the future, it becomes important to optimize experimental conditions for the total 
synthesis of hydroxylated xanthones, in order to achieve better yields in these reactions. 
Moreover, it is also necessary to improve the protocols and the reaction conditions of the 
Mannich reaction to overcome its limitations, making it more selective and applicable to any 
substrate, including to hydroxylated xanthones. 
According to the docking studies performed for the most active compound ICB1 with 
AChE, in the future, in order to optimize the dual activity of flavonic derivatives, some 
molecular modifications on the flavone scaffold may be carried out. With the purpose of 
exploring the importance of the presence and position of amino groups for the AChE 
inhibitory activity of flavones, other aminoflavones can be synthesized through the 
introduction of other amino groups on A ring at different positions.  
Considering the synthesis of aminoxanthones and taking into account that ICX2a 
showed interesting antioxidant and AChE inhibitory effects, other way for future work will 
possibly consist in the synthesis of other aminoxanthones by introduction of different amino 
groups on the xanthone scaffold, in order to afford xanthonic derivatives with better dual 
activity.  
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